Method for detecting target nucleic acid in sample
Probes with a target binding and barcode domain facilitate rapid and sensitive multiplex detection of nucleic acids by sequential binding and detection of complementary labels, addressing the limitations of current methods in accuracy and speed.
Patent Information
- Application Number
- JP2024143175
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-05-01
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-15
AI Technical Summary
Current methods for detecting nucleic acids in biological samples lack accuracy, speed, and sensitivity, particularly in multiplex detection, identification, and quantification.
The use of probes with a target binding domain and a barcode domain, capable of recognizing and binding specific regions of target nucleic acids, combined with a method involving multiple steps of binding, detecting, and removing complementary nucleic acid molecules with detectable labels to identify and quantify target nucleic acids.
Enables accurate, rapid, and sensitive multiplex detection and quantification of target nucleic acids, allowing for precise identification of specific regions without the need for amplification or conversion steps.
Smart Images

Figure 2024161084000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of U.S. Patent Application No. 62 / 337,074, filed May 16, 2016, and U.S. Patent Application No. 62 / 492,889, filed May 1, 2017, the entire contents of each of which are incorporated by reference.
[0002] Sequence Listing This application contains a Sequence Listing that has been submitted in ASCII format via EFS-Web, the entire contents of which are incorporated herein by reference. The ASCII copy, created on May 16, 2017, is named NATE-032001WO_ST25.text and has a file size of 22,780 bytes. [Background technology]
[0003] 2. Background of the Invention Although a variety of methods currently exist for detecting nucleic acids in biological samples, there remains a need for improved, accurate, rapid and sensitive methods for multiplexed detection, identification and quantification of target nucleic acids. The present invention addresses this need. Summary of the Invention [Problem to be solved by the invention]
[0004] The present invention provides probes, methods, kits and devices that provide accurate, rapid and sensitive multiplexed detection, identification and quantification of target nucleic acids in a sample. [Means for solving the problem]
[0005] One aspect of the present invention is a method for detecting at least one target nucleic acid in a sample, comprising a first step of contacting the sample with at least one probe capable of recognizing and binding to a first specific region of at least one target molecule, said at least one probe comprising a target binding domain and a barcode domain, said target binding domain comprising at least 4 nucleotides, preferably 6 or more nucleotides, and capable of recognizing and binding to a first specific region of a target nucleic acid, said target binding domain comprising a known nucleotide sequence; wherein said barcode domain comprises a nucleic acid sequence capable of being bound by a first complementary nucleic acid molecule, a first complementary nucleic acid molecule of a first reporter complex or a first hybridizing nucleic acid molecule, and a nucleic acid sequence capable of being bound by at least a second complementary nucleic acid molecule, a second complementary nucleic acid molecule of at least a second reporter complex or at least a second hybridizing nucleic acid molecule, wherein the sequence of said first binding region is different from the sequence of said at least a second binding region. The method further comprises the steps of: (2) binding a first complementary nucleic acid molecule comprising a detectable label or a first complementary nucleic acid molecule of a first reporter complex comprising a detectable label to the first binding region, thereby associating a detectable label with the first binding region; (3) detecting the detectable label associated with the first binding region; (4) removing the first detectable label or the first complementary nucleic acid molecule; (5) binding at least a second complementary nucleic acid molecule comprising a detectable label or at least a second complementary nucleic acid molecule of at least a second reporter complex comprising a detectable label to the at least second binding region, thereby associating a detectable label with the at least second binding region; and (6) detecting the detectable label associated with the at least second binding region; wherein a linear order or sequence of the detectable labels associated with the first binding region and the detectable labels associated with the at least second binding region identifies a specific region of the at least one target molecule, thereby detecting at least one target nucleic acid in the sample. Steps (4) and (5) may be carried out consecutively or simultaneously.
[0006] In one embodiment, removing the first complementary nucleic acid in step (4) comprises contacting the first binding region with a first hybridizing nucleic acid molecule that does not have a detectable label, thereby unbinding the first complementary nucleic acid molecule and binding a first hybridizing nucleic acid molecule that does not have a detectable label to the first binding region, or effecting a change in pH, salt concentration and / or temperature sufficient to remove the first complementary nucleic acid molecule.
[0007] In one aspect, the barcode domain comprises at least a third binding region comprising a nucleic acid sequence capable of being bound by at least a third complementary nucleic acid molecule, at least a third complementary nucleic acid molecule of at least a third reporter complex, or at least a third hybridizing nucleic acid molecule, wherein the sequence of said at least a third binding region is different from the sequence of another binding region.
[0008] In one embodiment, the method further comprises the steps of: (7) removing the second detectable label or the second complementary nucleic acid molecule; (8) binding at least a third complementary nucleic acid molecule comprising a detectable label or at least a third complementary nucleic acid molecule of at least a third reporter molecule comprising a detectable label to the at least third binding region, thereby associating a detectable label with the at least third binding region; and (9) detecting the detectable label associated with the at least third binding region, wherein a linear or sequential order of the detectable label associated with the first binding region, the detectable label associated with the at least second binding region, and the detectable label associated with the at least third binding region identifies a specific region of at least one target molecule, thereby detecting at least one target nucleic acid in the sample. Steps (7) and (8) may be sequential or simultaneous.
[0009] In one embodiment, removing the second complementary nucleic acid in step (7) comprises contacting the second binding region with a second hybridizing nucleic acid molecule that does not have a detectable label, thereby unbinding the second complementary nucleic acid molecule and binding the second hybridizing nucleic acid molecule that does not have a detectable label to the second binding region, or effecting a pH, salt concentration and / or temperature change sufficient to remove the second complementary nucleic acid molecule.
[0010] In some embodiments, the barcode domain can include at least a fourth binding region comprising a nucleic acid sequence that can be bound by at least a fourth complementary nucleic acid molecule, at least a fourth reporter complex, or at least a fourth hybridizing nucleic acid molecule, where the sequence of said at least a fourth binding region is different from the sequence of another binding region. In some embodiments, the barcode domain can include at least a fifth binding region comprising a nucleic acid sequence that can be bound by at least a fifth complementary nucleic acid molecule, at least a fifth reporter complex, or at least a fifth hybridizing nucleic acid molecule, where the sequence of said at least a fifth binding region is different from the sequence of another binding region. In some embodiments, the barcode domain can include at least a sixth binding region comprising a nucleic acid sequence that can be bound by at least a sixth complementary nucleic acid molecule, at least a sixth reporter complex, or at least a sixth hybridizing nucleic acid molecule, where the sequence of said at least a sixth binding region is different from the sequence of another binding region. In one aspect, the barcode domain can comprise at least a seventh binding region comprising a nucleic acid sequence capable of being bound by at least a seventh complementary nucleic acid molecule, at least a seventh reporter complex, or at least a seventh hybridizing nucleic acid molecule, wherein the sequence of said at least seventh binding region is different from the sequence of another binding region.
[0011] In one embodiment, the steps of removing each detectable label or complementary nucleic acid molecule; binding to each binding region a complementary nucleic acid molecule comprising a detectable label or a complementary nucleic acid molecule of a reporter complex comprising a detectable label, thereby associating a detectable label with each binding region; and detecting each detectable label associated with a binding region are repeated until each binding region in the barcode domain is sequentially bound by a complementary nucleic acid molecule comprising a detectable label and the detectable labels of the sequentially bound complementary nucleic acid molecules are detected, wherein the linear order or sequence of detectable labels bound to each binding region identifies a specific region of the at least one target molecule, thereby detecting the at least one target nucleic acid in the sample.
[0012] In one embodiment, a first hybridizing nucleic acid molecule that does not have a detectable label comprises at least the nucleic acid sequence of the first complementary nucleic acid molecule.
[0013] In one embodiment, the first binding region may be adjacent to at least one adjacent single-stranded polynucleotide or polynucleotide analogue. The first hybridizing nucleic acid molecule without a detectable label may further comprise a nucleic acid sequence that is partially complementary to at least one adjacent single-stranded polynucleotide adjacent to the first binding region.
[0014] In one embodiment, at least a second hybridizing nucleic acid molecule that does not have a detectable label comprises at least the nucleic acid sequence of said at least a second complementary nucleic acid molecule.
[0015] In one embodiment, the at least second binding region may be adjacent to at least one adjacent single-stranded polynucleotide or polynucleotide analogue. The at least second hybridizing nucleic acid molecule without a detectable label may comprise a nucleic acid sequence that is partially complementary to at least one adjacent single-stranded polynucleotide adjacent to the at least second binding region.
[0016] In certain embodiments, the barcode domain can comprise a synthetic backbone comprising a polysaccharide, a peptide, a peptide nucleic acid, a polypeptide, or a polynucleotide selected from single-stranded DNA, single-stranded RNA, or single-stranded PNA.
[0017] In certain embodiments, the at least one probe may comprise single- or double-stranded RNA, DNA, PNA or other polynucleotide analogues, or a PEG spacer between the target binding domain and the barcode domain.
[0018] In certain embodiments, the first complementary nucleic acid molecule of the first reporter complex, the at least second complementary nucleic acid molecule, and the at least second complementary nucleic acid molecule of the at least second reporter complex are independently RNA, DNA, PNA or other polynucleotide analogs.
[0019] In certain embodiments, the at least third complementary nucleic acid or the at least third complementary nucleic acid of the third reporter complex is RNA, DNA, PNA or other polynucleotide analogue.
[0020] In some embodiments, at least one nucleotide in the target binding domain may be a modified nucleotide or a nucleic acid analog. At least 2, at least 3, at least 4, at least 5 or at least 6 nucleotides in the target binding domain are modified nucleotides or nucleic acid analogs. Each nucleotide in the target binding domain may be a modified nucleotide or a nucleic acid analog. Such at least one modified nucleotide or at least one nucleic acid analog may also be a locked nucleic acid (LNA). At least one modified nucleotide or at least one nucleic acid analog may include a universal base.
[0021] In some embodiments, a target nucleic acid can be first immobilized on a substrate by binding a first location of the target nucleic acid with a first capture probe that includes a first affinity binding reagent that selectively binds to the substrate. In some embodiments, a target nucleic acid can be immobilized on a substrate after binding a first portion of the target nucleic acid to a probe by binding the first capture probe that includes a first affinity binding reagent that selectively binds to the substrate. In some embodiments, the first capture probe binds the target nucleic acid at a location on the target nucleic acid that is different from the location at which the at least one probe binds to the target nucleic acid. In some embodiments, the target nucleic acid can be elongated by applying a force (e.g., gravity, hydrodynamic force, electromagnetic force, flow stretching force, receding meniscus technique, or a combination thereof) sufficient to stretch the target nucleic acid immobilized on the substrate at a first location. The target nucleic acid can be further immobilized on the substrate by binding at least a second location of the target nucleic acid with at least a second capture probe that includes an affinity binding reagent that selectively binds to the substrate. Typically, the second capture probe binds to the target nucleic acid at a location on the target nucleic acid different from where the at least one probe and the first capture probe bind to the target nucleic acid. The target nucleic acid can be further immobilized to the substrate by binding at least a portion of the probe or a portion of a complementary nucleic acid molecule or a portion of a reporter complex to at least a third capture probe that includes a third affinity binding reagent that selectively binds to the substrate. The target nucleic acid can be further immobilized to the substrate by binding a portion of the probe, a portion of at least one complementary nucleic acid molecule, or a portion of at least one reporter complex to the substrate via a fourth affinity binding reagent. Exemplary affinity binding reagents include ligands, antigens, carbohydrates, receptors, lectins, antibodies, biotin, avidin, haptens, and nucleic acids with known sequences. The target nucleic acid can be immobilized to the substrate at about 3 to at least 10 locations. Once the second location of the target nucleic acid is immobilized to the substrate, the force can be removed. In some embodiments, the immobilized target nucleic acid is elongated.
[0022] In some embodiments, the first capture probe can include a second affinity reagent.
[0023] In certain embodiments, the second affinity reagent of the first capture probe is different from the first affinity reagent of at least one of the probes.
[0024] In certain embodiments, the first capture probe can further comprise a third affinity reagent that is different from the second affinity reagent.
[0025] In certain embodiments, the first affinity reagent, the second affinity reagent and the third affinity reagent are different.
[0026] In one embodiment, the number of nucleotides in the target binding domain is equal to the number of different binding regions in the barcode domain.
[0027] In some embodiments, the number of nucleotides in the target binding domain is at least one greater than the number of distinct binding regions in the barcode domain.
[0028] In some embodiments, the number of nucleotides in the target binding domain is at least twice the number of binding regions in the barcode domain.
[0029] In one embodiment, the number of nucleotides in the target binding domain is eight and the number of binding regions in the barcode domain is three.
[0030] In some embodiments, the number of nucleotides in the target binding domain is at least one less than the number of distinct binding regions in the barcode domain.
[0031] In certain embodiments, the target binding domain of the probe comprises at least 6 nucleotides, or at least 8 nucleotides.
[0032] In certain embodiments, the target binding domain of the probe comprises 10-100, 20-60 or 3550 nucleotides.
[0033] In some embodiments, at least a first binding region branches off from a first location on the barcode domain. In some embodiments, at least a second binding region branches off from at least a second location on the barcode domain. In some embodiments, each binding region branches off from one location on the barcode domain. The barcode domain comprises a first location comprising at least two first binding regions, wherein the at least two first binding regions comprise identical nucleic acid sequences that are bindable by a first complementary nucleic acid molecule or a first complementary nucleic acid molecule of a first reporter complex. The barcode domain may comprise at least a second location comprising at least two second binding regions, wherein the at least two second binding regions comprise identical nucleic acid sequences that are bindable by at least a second complementary nucleic acid molecule or a second complementary nucleic acid molecule of a second reporter complex. The barcode domain may comprise at least a third location comprising at least two third binding regions, wherein the at least two third binding regions comprise identical nucleic acid sequences that are bindable by at least a third complementary nucleic acid molecule or a third complementary nucleic acid molecule of a third reporter complex.
[0034] In some embodiments, each position in the barcode domain may contain the same number of binding regions. In some embodiments, at least one position in the barcode domain may contain multiple binding regions. Each position in the barcode domain may contain multiple binding regions.
[0035] In some embodiments, at least one position in the barcode domain may contain more binding regions than another position.
[0036] In one embodiment, at least one location on the barcode domain may contain 1-50 copies of the binding region, for example, each location on the barcode domain may contain 1-50 copies of the binding region.
[0037] The at least one probe can comprise multiple copies of a target binding domain operably linked to a barcode domain.
[0038] In one embodiment, each reporter complex that includes a detectable label can include a complementary nucleic acid molecule directly linked to a first nucleic acid molecule.
[0039] In certain aspects, a reporter complex comprising a detectable label can comprise a complementary nucleic acid molecule indirectly linked to a first nucleic acid molecule via a nucleic acid spacer.
[0040] In some embodiments, the nucleic acid molecule can include a complementary nucleic acid molecule indirectly linked to the first nucleic acid molecule via a polymer spacer that has similar mechanical properties to the nucleic acid spacer.
[0041] In one embodiment, each reporter complex containing a detectable label comprises a complementary nucleic acid molecule indirectly linked to a starting nucleic acid molecule via a cleavable linker.
[0042] In certain embodiments, the cleavable linker is photocleavable, chemically cleavable, or enzymatically cleavable. Typically, each cleavable linker is cleavable independently of all other linkers.
[0043] In some embodiments, the photocleavable linker is cleaved by a light source such as an arc lamp, a laser, a focused UV light source, or a light emitting diode.
[0044] In certain embodiments, each complementary nucleic acid molecule can comprise from about 8 nucleotides to about 20 nucleotides, for example, about 10 nucleotides, about 12 nucleotides, about 14 nucleotides.
[0045] In certain embodiments, each first nucleic acid molecule can hybridize to at least one second nucleic acid molecule, e.g., at least two second nucleic acid molecules, at least three second nucleic acid molecules, at least four second nucleic acid molecules, at least five second nucleic acid molecules, at least six second nucleic acid molecules. One or more of the second nucleic acid molecules can comprise at least one detectable label.
[0046] In some embodiments, the second nucleic acid molecule can include a cleavable linker. For example, the cleavable linker can be photocleaved, chemically cleaved, or enzymatically cleaved. In some embodiments, the various second nucleic acid molecules hybridized to the first nucleic acid molecule include the same cleavable linker, non-cleavable linkers, combinations of various cleavable linkers, and combinations of various cleavable and non-cleavable linkers.
[0047] In certain embodiments, each second nucleic acid molecule can hybridize to at least one third nucleic acid molecule comprising at least one detectable label, e.g., at least 2, at least 3, at least 4, at least 5, at least 6, or at least 7 third nucleic acid molecules comprising at least one detectable label.
[0048] In one embodiment, at least one second nucleic acid molecule may comprise a region that does not hybridize to the first nucleic acid molecule and does not hybridize to the third nucleic acid molecule. In one embodiment, each second nucleic acid molecule may comprise a region that does not hybridize to the first nucleic acid molecule and does not hybridize to the third nucleic acid molecule. The region that does not hybridize to the first nucleic acid molecule and does not hybridize to the third nucleic acid molecule may comprise the nucleotide sequence of a complementary nucleic acid molecule that is directly linked to the first nucleic acid molecule. The region that does not hybridize to the first nucleic acid molecule and does not hybridize to the third nucleic acid molecule may be located at the end of the second nucleic acid molecule. The region that does not hybridize to the first nucleic acid molecule and does not hybridize to the third nucleic acid molecule may comprise about 8 to about 20 nucleotides, for example about 12 nucleotides.
[0049] In some embodiments, at least one target nucleic acid is selected from the group consisting of 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000 or more different target nucleic acids, and any number in between.
[0050] In certain embodiments, the method may further comprise detecting at least one target protein in the sample.
[0051] In some embodiments, at least one target protein is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000 or more, and any number of different target nucleic acids proteins in between.
[0052] The terms "one or more," "at least one," and the like mean at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000 or more, and any number in between, but is not intended to be limited to such.
[0053] The terms "plurality," "at least two," "two or more," "at least a second," and the like mean at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000 or more, and any number in between. Thus, "at least two label attachment positions" includes, but is not limited to, 2 label attachment positions, 4 label attachment positions, 6 label attachment positions, 8 label attachment positions, 10 label attachment positions, or more.
[0054] The present disclosure provides a method for detecting at least one target nucleic acid in a sample, comprising: (1) contacting the sample with at least one probe capable of recognizing and binding to a first specific region of at least one target molecule, wherein the at least one probe comprises a target binding domain and a barcode domain, the target binding domain comprises at least four nucleotides and is capable of recognizing and binding to a first specific region of the target nucleic acid, and the target binding domain comprises a known nucleotide sequence; the barcode domain comprises a first binding region comprising a nucleic acid sequence bound by a first complementary nucleic acid molecule or a first complementary nucleic acid molecule of a first reporter complex, and at least a second binding region comprising a barcode domain; and at least a second binding region bound by a complementary nucleic acid molecule of at least a second reporter complex; the at least a first complementary nucleic acid molecule or the first complementary nucleic acid molecule of the first reporter complex comprises a first detectable label, thereby associating a detectable label with the first binding region; the at least a second complementary nucleic acid molecule or the at least a second complementary nucleic acid molecule of the at least a second reporter complex comprises a second detectable label, thereby associating a detectable label with the at least a second binding region; wherein a sequence of the first binding region is different from a sequence of the at least a second binding region; (2) (3) detecting a first detectable label associated with the first binding region and a second detectable label associated with the at least second binding region; (4) removing the first detectable label; and (5) detecting the second detectable label associated with the at least second binding region; wherein the linear or sequential order of the first detectable label associated with the first binding region and the second detectable label associated with the at least second binding region identifies a specific region of at least one target molecule, thereby detecting at least one target nucleic acid in the sample.
[0055] The detection in step (4) can include subtracting a signal resulting from the second detectable label associated with at least the second binding region in step (4) from a signal resulting from detecting a first detectable label associated with the first binding region and a second detectable label associated with the at least second binding region in step (2).
[0056] The barcode domain can comprise a first binding region comprising a nucleic acid sequence bound by a first complementary nucleic acid molecule or a first complementary nucleic acid molecule of a first reporter complex, a second binding region bound by at least a second complementary nucleic acid molecule or at least a second complementary nucleic acid molecule of at least a second reporter complex, and at least a third binding region bound by at least a third complementary nucleic acid molecule or at least a third complementary nucleic acid molecule of at least a third reporter complex. wherein said first complementary nucleic acid molecule or first complementary nucleic acid molecule of a first reporter complex comprises a first detectable label, thereby associating a detectable label with said first binding region; wherein said second complementary nucleic acid molecule or second complementary nucleic acid molecule of at least a second reporter complex comprises a second detectable label, thereby associating a detectable label with said at least a second binding region; said third complementary nucleic acid molecule or third complementary nucleic acid molecule of at least a third reporter complex comprises a third detectable label, thereby associating a detectable label with said third binding region; wherein said at least a third binding region, at least a second binding region and at least a third binding region are different; (2) detecting the first detectable label associated with said first binding region, the second detectable label associated with said at least a second binding region and the third detectable label associated with said at least a third detectable region; (3) removing said first detectable label; (4) detecting the second detectable label associated with said at least a second binding region and the third detectable label associated with said at least a third binding region; (5) removing the second detectable label; (6) detecting a third detectable label associated with the at least third binding region; wherein the linear order or sequence of the first detectable label associated with the first binding region, the second detectable label associated with the second binding region, and the third detectable label associated with the third binding region identifies a particular region of the at least one target molecule, thereby detecting at least one target nucleic acid in the sample.
[0057] The detection in step (4) can include subtracting a signal from the second detectable label associated with the at least second binding region and the at least third detectable label associated with the third binding region in step (4) from a signal from the first detectable label associated with the first binding region, the second detectable label associated with the at least second binding region, and the at least third binding label associated with the third binding region in step (2).
[0058] The detection in step (6) can include subtracting a signal from at least a third detectable label associated with the third binding region in step (6) from the signals from the second detectable label associated with said at least second binding region and the at least a third detectable label associated with said third binding region in step (4).
[0059] The disclosure also provides a method for detecting at least one target nucleic acid in a sample, the method comprising: (1) contacting the sample with at least one probe capable of recognizing and binding to a first specific region of at least one target molecule, wherein the at least one probe comprises a target binding domain and a barcode domain, wherein the target binding domain comprises at least four nucleotides and is capable of recognizing and binding to a first specific region of the target nucleic acid, and wherein the target binding domain comprises a known nucleotide sequence; wherein the barcode domain comprises a first binding region comprising a nucleic acid sequence that is bindable by a first complementary nucleic acid molecule, a first complementary nucleic acid molecule of a first reporter complex, or a first hybridizing nucleic acid molecule, and at least a second binding region comprising a nucleic acid sequence that is bindable by at least a second complementary nucleic acid molecule, at least a second complementary nucleic acid molecule of at least a second reporter complex, or at least a second hybridizing nucleic acid molecule; wherein the sequence of the first binding region is different from the sequence of the at least second binding region; (2) The method includes: binding a first complementary nucleic acid molecule comprising a first detectable label or a first complementary nucleic acid molecule of a first reporter complex comprising a first detectable label to the first binding region, thereby associating a detectable label with the first binding region; (3) detecting the first detectable label associated with the first binding region; (4) removing the first detectable label or the first complementary nucleic acid molecule; (5) binding at least a second complementary nucleic acid molecule comprising a second detectable label or at least a second complementary nucleic acid molecule of at least a second reporter complex comprising a second detectable label to the at least second binding region, thereby associating a detectable label with the valley binding region; and (6) detecting the second detectable label associated with the at least second binding region; wherein the linear or sequential order of the second detectable label associated with the first binding region and the second detectable label associated with the at least second binding region identifies a specific region of at least one target molecule, thereby detecting at least one target nucleic acid in the sample. Steps (4) and (5) can occur sequentially or simultaneously.
[0060] The barcode domain can comprise at least a third binding region comprising a nucleic acid sequence capable of being bound by at least a third complementary nucleic acid molecule, at least a third reporter complex or at least a third hybridizing nucleic acid molecule, wherein the sequence of the at least third binding region is different from the sequences of the other binding regions.
[0061] The method includes (7) removing the second detectable label or the second complementary nucleic acid molecule; (8) binding at least a third complementary nucleic acid molecule comprising a third detectable label or at least a third complementary nucleic acid molecule of at least a third reporter complex comprising a third detectable label to the at least third binding region, thereby associating a detectable label with the at least third binding region; and (9) detecting the third detectable label associated with the at least third binding region; wherein the linear order or sequence of the first detectable label associated with the first binding region, the second detectable label associated with the at least second binding region, and the third detectable label associated with the at least third binding region identifies a specific region of the at least one target molecule, thereby detecting at least one target nucleic acid in the sample. Steps (7) and (8) may occur sequentially or simultaneously.
[0062] The removal of the first complementary nucleic acid in step (4) can include: (a) contacting a first binding region with a first hybridizing nucleic acid molecule that does not contain a detectable label, thereby binding the first hybridizing nucleic acid molecule that does not contain the detectable label to the first binding region while leaving the first complementary nucleic acid molecule unbound; and (b) applying a change in pH, salt concentration, and / or temperature sufficient to remove the first complementary nucleic acid molecule.
[0063] The removal of the second complementary nucleic acid in step (7) can include (a) contacting the second binding region with a second hybridizing nucleic acid molecule that does not contain a detectable label, thereby binding the second hybridizing nucleic acid molecule that does not contain the detectable label to the second binding region while leaving the second complementary nucleic acid molecule unbound; and (b) applying a change in pH, salt concentration, and / or temperature sufficient to remove the first complementary nucleic acid molecule.
[0064] The barcode domain can further comprise at least a fourth binding region comprising a nucleic acid sequence capable of being bound by at least a fourth complementary nucleic acid molecule, at least a fourth reporter complex, or at least a fourth hybridizing nucleic acid molecule; wherein the sequence of the at least fourth binding region is different from the sequences of the other binding regions.
[0065] The barcode domain can further comprise at least a fifth binding region comprising a nucleic acid sequence capable of being bound by at least a fifth complementary nucleic acid molecule, at least a fifth reporter complex, or at least a fifth hybridizing nucleic acid molecule; wherein the sequence of the at least fifth binding region is different from the sequences of the other binding regions.
[0066] The barcode domain can further comprise at least a sixth binding region comprising a nucleic acid sequence capable of being bound by at least a sixth complementary nucleic acid molecule, at least a sixth reporter complex or at least a sixth hybridizing nucleic acid molecule; wherein the sequence of the at least sixth binding region is different from the sequences of the other binding regions.
[0067] The barcode domain can further comprise at least a seventh binding region comprising a nucleic acid sequence capable of being bound by at least a seventh complementary nucleic acid molecule, at least a seventh reporter complex or at least a seventh hybridizing nucleic acid molecule; wherein the sequence of the at least seventh binding region is different from the sequences of the other binding regions.
[0068] The steps of (a) removing each detectable label or complementary nucleic acid molecule; (b) binding to each binding region with a complementary nucleic acid molecule comprising a detectable label or a complementary nucleic acid molecule of a reporter complex comprising a detectable label, thereby associating a detectable label with each binding region; and (c) detecting each detectable label associated with said binding region are repeated until each binding region in a barcode domain is sequentially bound by a complementary nucleic acid molecule comprising a detectable label and the detectable labels of the sequentially bound complementary nucleic acid molecules are detected; wherein the linear order or sequence of the detectable labels associated with each binding region identifies a specific region of the at least one target molecule, thereby detecting at least one target nucleic acid in the sample.
[0069] The first hybridizing nucleic acid molecule, which does not have a detectable label, can include at least the nucleic acid sequence of the first complementary nucleic acid molecule.
[0070] The first binding region can be flanked by at least one contiguous single-stranded polynucleotide or polynucleotide analogue.
[0071] The first hybridizing nucleic acid molecule without a detectable label can further comprise a nucleic acid sequence that is partially complementary to at least one adjacent single-stranded polynucleotide adjacent to the first binding region.
[0072] The at least a second hybridizing nucleic acid molecule that does not have a detectable label can comprise at least the nucleic acid sequence of at least a second complementary nucleic acid molecule.
[0073] The at least second binding region can be flanked by at least one contiguous single-stranded polynucleotide or polynucleotide analogue.
[0074] The second hybridizing nucleic acid molecule, which does not have a detectable label, can comprise a nucleic acid sequence that is partially complementary to at least one adjacent single-stranded polynucleotide adjacent to the at least second binding region.
[0075] Removing the first detectable label in step (3) can include contacting the first complementary nucleic acid molecule, or the first complementary nucleic acid molecule of the first reporter complex, under a force at a location on the first complementary nucleic acid molecule sufficient to release the first detectable label.
[0076] Removing the second detectable label in step (5) can include contacting the second complementary nucleic acid molecule, or the first complementary nucleic acid molecule of the second reporter complex, under a force at a location on the second complementary nucleic acid molecule sufficient to liberate the second detectable label.
[0077] Removing the first detectable label in step (4) can include contacting the first complementary nucleic acid molecule, or at least the first complementary nucleic acid molecule of the first reporter complex, under a force at a location on the first complementary nucleic acid molecule sufficient to release the first detectable label.
[0078] Removing the second detectable label in step (7) can include contacting the second complementary nucleic acid molecule, or at least the second complementary nucleic acid molecule of the second reporter complex, under a force to a location on the second complementary nucleic acid molecule sufficient to liberate the second detectable label.
[0079] At least one of the first complementary nucleic acid molecule, the first complementary nucleic acid molecule of the first reporter complex, the at least second complementary nucleic acid molecule, the second complementary nucleic acid molecule of the at least second reporter complex, the at least third complementary nucleic acid molecule, the at least third complementary nucleic acid molecule of the at least third reporter complex may comprise at least one cleavable linker.
[0080] The at least one cleavable linker can be independently selected from the group consisting of photocleavable, chemically cleavable, and enzymatically cleavable. Each cleavable linker is cleavable independently of all other linkers. The photocleavable linker can be cleaved by a light source selected from the group consisting of an arc lamp, a laser, a focused UV light source, and a light emitting diode. The force can be light.
[0081] The disclosed methods can further include washing the probe from at least one target nucleic acid. The washing can include a change in pH, salt concentration and / or temperature sufficient to remove the probe from the target molecule.
[0082] The method of the present disclosure is further characterized in that (i) contacting the sample with at least a second probe capable of recognizing and binding to a second specific region of the at least one target molecule, wherein the second specific region is different from the first specific region of the at least one target molecule; (ii) contacting the sample with at least a second copy of the first probe capable of recognizing and binding to the first specific region of the at least one target molecule; or (iii) contacting the sample with at least a third probe capable of recognizing and binding to a first specific region of at least a second target molecule, wherein the at least second target molecule is different from the at least one target molecule; wherein the probe comprises a target binding domain and a barcode domain, the target binding domain comprising at least four nucleotides; and the barcode domain comprises a barcode domain comprising a first binding region comprising a nucleic acid sequence bound by a first complementary nucleic acid molecule or a first complementary nucleic acid molecule of a first reporter complex, and at least a second binding region bound by at least a second complementary nucleic acid molecule or at least a second complementary nucleic acid molecule of at least a second reporter complex.
[0083] The disclosed method further comprises: (i) contacting the sample with at least a second probe capable of recognizing and binding to a second specific region of the at least one target molecule, wherein the second specific region is different from the first specific region of the at least one target molecule; (ii) contacting the sample with at least a second copy of the first probe capable of recognizing and binding to the first specific region of the at least one target molecule; or (iii) The sample is contacted with at least a third probe capable of recognizing and binding to a first specific target region of at least a second target molecule, wherein the at least a second target molecule is different from the at least one target molecule; wherein the probe comprises a target binding domain and a barcode domain, wherein the target binding domain comprises at least four nucleotides; and wherein the barcode domain comprises a first binding region comprising a nucleic acid sequence that can be bound by a first complementary nucleic acid molecule, a first complementary nucleic acid molecule of a first reporter complex, or a first hybridizing nucleic acid molecule, and at least a second binding region comprising a nucleic acid sequence that can be bound by at least a second complementary nucleic acid molecule, at least a second complementary nucleic acid molecule of at least a second reporter complex, or at least a second hybridizing nucleic acid molecule.
[0084] The method may further comprise repeating steps (1)-(6) of claim 3 with at least a second probe, at least a second copy of the first probe, or at least a third probe. The method may further comprise repeating steps (1)-(9) with at least a second probe, at least a second copy of the first probe, or at least a third probe. After washing the probe from the at least first target nucleic acid, steps (1)-(6) or steps (1)-(9) may be repeated up to about 50 times.
[0085] The detectable label may comprise multiple moieties, each of which can be identified by their emission spectrum. The detectable label may be a quantum dot, a fluorescent moiety, a colorimetric moiety, or a combination thereof. Preferably, the detectable label may comprise a fluorescent moiety. The emission spectrum of each moiety may be the same or different. The emission spectrum of at least one moiety may be different from that of the other moieties. In a preferred aspect, the signal is the emission spectrum. In some embodiments, one or more emission spectra of the label are the detectable signal.
[0086] The barcode domain can comprise a polysaccharide, a peptide, a peptide nucleic acid, a polypeptide, or a synthetic backbone comprising a polynucleotide selected from single-stranded DNA, single-stranded RNA, or single-stranded PNA. At least one probe can comprise a single- or double-stranded RNA, DNA, PNA, or other polynucleotide analog, or a PEG spacer between the target binding domain and the barcode domain. In a preferred aspect, the spacer is double-stranded DNA.
[0087] The first complementary nucleic acid molecule, the first complementary nucleic acid molecule of the first reporter complex, the at least second complementary nucleic acid molecule, the at least second complementary nucleic acid molecule of the at least second reporter complex can independently be RNA, DNA, PNA or other polynucleotide analogues. The at least third complementary nucleic acid or the at least third complementary nucleic acid of the third reporter complex can be RNA, DNA, PNA or other polynucleotide analogues.
[0088] At least one nucleotide in the target binding domain can be a modified nucleotide or nucleic acid analogue. At least 2, at least 3, at least 4, at least 5 or at least 6 nucleotides in the target binding domain can be modified nucleotides or nucleic acid analogues. Each nucleotide in the target binding domain can be a modified nucleotide or nucleic acid analogue. Each nucleotide in the target binding domain can be a modified nucleotide or nucleic acid analogue except for the first and last nucleotides.
[0089] The at least one modified nucleotide or the at least one nucleic acid analogue may be a locked nucleic acid (LNA). The at least one modified nucleotide or the at least one nucleic acid analogue may comprise a universal base.
[0090] The target nucleic acid is first immobilized on a substrate and then contacted with a probe by binding at least a first location of the target nucleic acid with a first capture probe that comprises a first affinity binding reagent that selectively binds to the substrate, where the first capture probe binds the target nucleic acid at a location on the target nucleic acid that is different from the location at which at least one probe binds the target nucleic acid.
[0091] The target nucleic acid can be immobilized to a substrate after binding at least a first location on the target nucleic acid with a first capture probe that comprises a first affinity binding reagent that selectively binds to a substrate, where the first capture probe binds the target nucleic acid at a location on the target nucleic acid that is different from the location at which at least one probe binds to the target nucleic acid.
[0092] The target nucleic acid can be elongated by applying a force sufficient to stretch the target nucleic acid immobilized on the substrate at a first location, the force can be gravity, a hydrodynamic force, an electromagnetic force, a flow stretching technique, a receding meniscus technique, or a combination thereof.
[0093] The target nucleic acid can be further immobilized to the substrate by binding at least a second location of the target nucleic acid with at least a second capture probe comprising a second affinity binding reagent that selectively binds to the substrate, where the second capture probe binds the target nucleic acid at a location on the target nucleic acid that is different from the location at which the at least one probe and the first capture probe bind the target nucleic acid.
[0094] The target nucleic acid can be further immobilized to the substrate by binding at least a portion of the probe or a portion of a complementary nucleic acid molecule or reporter complex to at least a third capture probe that comprises a third affinity binding reagent that selectively binds to the substrate.
[0095] The probe, at least one complementary nucleic acid or at least one reporter complex may comprise a fourth affinity binding reagent.
[0096] The target nucleic acid can be further immobilized to the substrate by binding a portion of the probe, at least one complementary nucleic acid molecule, or a portion of at least one reporter complex to the substrate via a fourth affinity binding reagent.
[0097] The force can be removed after the second location of the target nucleic acid is immobilized on the substrate.
[0098] The affinity binding reagents can be independently selected from the group consisting of ligands, antigens, carbohydrates, receptors, lectins, antibodies, biotin, avidin, haptens, and nucleic acids of known sequence.
[0099] The first capture probe can comprise a target binding domain comprising 20-60 nucleotides, where the first capture probe binds the target nucleic acid at a location on the target nucleic acid that is different from the location at which the at least one probe binds the target nucleic acid.
[0100] The first affinity binding reagent can be different from the second affinity binding reagent.
[0101] At least one of the first affinity binding reagent, the second affinity binding reagent, the third affinity binding reagent and the fourth affinity binding reagent can be different from the other affinity binding reagents.
[0102] The number of nucleotides in the target binding domain can be at least twice the number of binding regions in the barcode domain. For example, the number of nucleotides in the target binding domain can be 8 and the number of binding regions in the barcode domain can be 3. The target binding domain can comprise at least 6 nucleotides. The target binding domain can comprise at least 8 nucleotides. The target binding domain can comprise 10-100 nucleotides. The target binding domain can comprise 20-60 nucleotides. The target binding domain can comprise 35-50 nucleotides.
[0103] Each complementary nucleic acid molecule can contain about 8 nucleotides to about 20 nucleotides. Each complementary nucleic acid molecule can contain about 12 nucleotides. Each complementary nucleic acid molecule can contain about 14 nucleotides.
[0104] The first binding region can diverge from at least a first position on the barcode domain. The at least second binding region can diverge from at least a second position on the barcode domain. Each binding region can diverge from one position on the barcode domain.
[0105] The barcode domain can comprise a first location comprising at least two first binding regions, wherein the at least two first binding regions comprise identical nucleic acid sequences that are bindable by a first complementary nucleic acid molecule or a first complementary nucleic acid molecule of a first reporter complex.
[0106] The barcode domain can comprise at least a second location comprising at least two second binding regions, wherein the at least two second binding regions comprise identical nucleic acid sequences that are bindable by at least a second complementary nucleic acid molecule or at least a second complementary nucleic acid molecule of at least a second reporter complex.
[0107] The barcode domain can comprise at least a third location comprising at least two third binding regions, wherein the at least two third binding regions comprise identical nucleic acid sequences that are bindable by at least a third complementary nucleic acid molecule or at least a third complementary nucleic acid molecule of at least a third reporter complex.
[0108] Each position in the barcode domain can contain the same number of binding regions. At least one position in the barcode domain can contain multiple binding regions. At least one position in the barcode domain can contain a greater number of binding regions than another position.
[0109] At least one of the probes can comprise multiple copies of a target binding domain operably linked to a barcode domain.
[0110] Each reporter complex can comprise a detectable label comprising a complementary nucleic acid molecule directly linked to a first nucleic acid molecule. Each reporter complex can comprise a detectable label comprising a complementary nucleic acid molecule indirectly linked to a first nucleic acid molecule via a nucleic acid spacer. Each reporter complex can comprise a detectable label comprising a complementary nucleic acid molecule indirectly linked to a first nucleic acid molecule via a polymer spacer having mechanical properties similar to the nucleic acid spacer. Each reporter complex can comprise a detectable label comprising a complementary nucleic acid molecule indirectly linked to a first nucleic acid molecule via a cleavable linker.
[0111] The cleavable linkers can be independently selected from photocleavable, chemically cleavable, and enzymatically cleavable. Each cleavable linker can be cleaved independently of all other linkers. The photocleavable linker can be cleaved by a light source selected from the group consisting of an arc lamp, a laser, a focused UV light source, and a light emitting diode.
[0112] Each first nucleic acid molecule can hybridize to at least 1, at least 2, at least 3, at least 4, at least 5, at least 6 second nucleic acid molecules.
[0113] The one or more second nucleic acid molecules can comprise at least one detectable label. Each second nucleic acid molecule can hybridize to at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7 third nucleic acid molecules. At least one second nucleic acid molecule can comprise a region that does not hybridize to the first nucleic acid molecule and does not hybridize to the third nucleic acid molecule. The region that does not hybridize to the first nucleic acid molecule and does not hybridize to the third nucleic acid molecule can comprise a nucleotide sequence of a complementary nucleic acid molecule directly linked to the first nucleic acid molecule. The region that does not hybridize to the first nucleic acid molecule and does not hybridize to the third nucleic acid molecule can be located at the end of the second nucleic acid molecule. The region that does not hybridize to the first nucleic acid molecule and does not hybridize to the third nucleic acid molecule can comprise about 8 nucleotides to about 20 nucleotides. The region that does not hybridize to the first nucleic acid molecule and does not hybridize to the third nucleic acid molecule can comprise about 12 nucleotides.
[0114] The present disclosure provides kits containing reagents for carrying out any of the methods disclosed herein.
[0115] Any of the above aspects and embodiments may be combined with any of the other aspects or embodiments.
[0116] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0117] As used herein, unless expressly stated otherwise, the singular form of a word includes the plural form of that word. By way of example, the terms "a," "an," and "the" are interpreted as either singular or plural, and the term "or" is interpreted as inclusive. By way of example, "an element" means one or more elements.
[0118] Throughout the specification, the terms "comprise" or "contain" or variations such as "comprise" will be interpreted to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of other elements, integers or steps, or groups of elements, integers or steps.
[0119] "About" can be interpreted as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05% or 0.01% of the stated value. Unless expressly stated otherwise, all numerical values provided herein are modified by the term "about."
[0120] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patent specifications, and other references mentioned herein are incorporated by reference in their entirety. Any reference cited herein is not admitted to be prior art to the present invention. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are merely illustrative and not intended to be limiting. Other features and advantages of the present invention will be apparent from the following detailed description and claims.
[0121] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication will be provided by the Department upon request and payment of the necessary fee.
[0122] The above and additional features will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings. [Brief description of the drawings]
[0123] [Figure 1] FIG. 1 shows an overview of a typical probe of the present invention.
[0124] [Diagram 2] FIG. 2 shows a schematic diagram of an exemplary probe of the present invention.
[0125] [Diagram 3] FIG. 3 shows a schematic diagram of a typical probe of the present invention.
[0126] [Figure 4] FIG. 4 shows a schematic diagram of an exemplary probe of the present invention.
[0127] [Figure 5A] FIG. 5A illustrates the steps of the method of the present invention.
[0128] [Figure 5B] FIG. 5B illustrates the steps of the method of the present invention beginning with FIG. 5A.
[0129] [Figure 5C] FIG. 5C illustrates the steps of the method of the present invention beginning with FIG. 5A.
[0130] [Figure 5D] FIG. 5D illustrates the steps of the method of the present invention beginning with FIG. 5A.
[0131] [Figure 6]6 illustrates an example of a one-step purification method in which a probe and a capture probe are attached together to a target nucleic acid, thereby forming a tripartite complex, which is purified by immobilization to a substrate via the affinity reagent of the capture probe.
[0132] [Figure 7] FIG. 7 illustrates an example of a one-step purification method in which a capture probe containing a binding moiety is added to a target nucleic acid, the capture probe-target nucleic acid complex is then immobilized to a substrate via the binding moiety, and a probe is then bound to the immobilized complex.
[0133] [Figure 8A] Figure 8A illustrates an example of a multi-step purification method, in which a probe containing an affinity reagent is bound to a target nucleic acid, and then the probe-target nucleic acid complex is purified by the affinity reagent of the probe (not shown). A capture probe containing a binding moiety is then bound to the complex to form a ternary complex. Finally, the ternary complex is purified by immobilization to a substrate via the capture probe binding moiety.
[0134] [Figure 8B] Figure 8B illustrates another example of a multi-step purification method, in which a probe containing an affinity reagent is bound to a target nucleic acid, and then the probe-target nucleic acid complex is purified by the affinity reagent of the probe (not shown). A capture probe, which has been previously immobilized to a substrate by a binding moiety, captures the purified probe-target nucleic acid complex, thereby forming a purified and immobilized ternary complex.
[0135] [Figure 8C]Figure 8C illustrates another example of a multi-step purification method, in which a probe containing an affinity reagent is bound to a target nucleic acid, and then the probe-target nucleic acid complex is purified by the affinity reagent of the probe (not shown). A capture probe containing a binding moiety and an affinity reagent (where the affinity reagent is different from the affinity reagent on the probe) is then bound to the complex to form a ternary complex. The affinity reagent on the capture probe purifies the ternary complex (not shown). Finally, the purified ternary complex is immobilized to a substrate via the binding moiety on the capture probe.
[0136] [Figure 8D] Figure 8D illustrates another example of a multi-step purification method, in which a capture probe containing a binding moiety and an affinity reagent is bound to a target nucleic acid, and then the capture probe-target nucleic acid complex is purified by the affinity reagent of the capture probe (not shown). A probe is then bound to the complex to form a ternary complex. Finally, the ternary complex is purified by immobilization to a substrate via the binding moiety of the capture probe.
[0137] [Figure 8E] Figure 8E illustrates another example of a multi-step purification method, in which a capture probe containing a binding moiety and an affinity reagent is bound to a target nucleic acid, and then the capture probe-target nucleic acid complex is purified by the affinity reagent of the capture probe (not shown). The complex is then bound by a probe containing an affinity reagent (wherein the affinity reagent is different from the affinity reagent on the capture probe) to form a ternary complex. The affinity reagent on the probe purifies the ternary complex. Finally, the purified ternary complex is immobilized to a substrate via the binding moiety on the capture probe.
[0138] [Figure 9A] FIG. 9A shows the first step of the method of the present invention.
[0139] [Figure 9B] FIG. 9B shows a schematic of a reporter complex containing a detectable label.
[0140] [Figure 9C] FIG. 9C shows multiple reporter complexes, each containing a detectable label.
[0141] [Figure 9D] FIG. 9D shows a further step in the method beginning with FIG. 9A.
[0142] [Figure 9E] FIG. 9E shows a further step in the method beginning with FIG. 9A.
[0143] [Figure 9F] FIG. 9F shows a further step in the method beginning with FIG. 9A.
[0144] [Figure 10] Figure 10 shows another diagram of the process shown in Figures 9D and 9E and representative data obtained therefrom. The probe fragment shown has the sequence of SEQ ID NO:70.
[0145] [Figure 11] Figure 11 shows a variation of the method shown in Figure 10. Similarly, the fragment of the probe shown has the sequence of SEQ ID NO:70.
[0146] [Figure 12A] FIG. 12A shows various designs of reporter complexes of the invention.
[0147] [Figure 12B] FIG. 12B shows the fluorescence counts obtained from the reporter complexes shown in FIG. 12A.
[0148] [Figure 12C] FIG. 12C shows an exemplary recipe for constructing a reporter complex of the invention.
[0149] [Figure 13A] Figure 13A shows the design of a reporter complex with an "extra handle".
[0150] [Figure 13B] Figure 13B shows the fluorescence counts obtained from a reporter complex with an "extra handle".
[0151] [Figure 14A] FIG. 14A shows the hybridization kinetics of two exemplary designs of a reporter complex of the invention.
[0152] [Figure 14B] FIG. 14B shows the hybridization kinetics of two exemplary designs of a reporter complex of the invention.
[0153] [Figure 15A] FIG. 15A depicts the miniature barcode probe design.
[0154] [Figure 15B] FIG. 15B shows data obtained with the method of the invention when the probe was provided at a low concentration.
[0155] [Figure 15C] FIG. 15C shows data obtained with the method of the invention when the probe was provided at high concentration.
[0156] [Figure 16A] FIG. 16A shows data obtained with a method of the invention in which multiple target nucleic acids are detected simultaneously.
[0157] [Figure 16B] FIG. 16B compares data obtained with the method of the invention and with a probe containing a detectable label.
[0158] [Figure 17A]FIG. 17A demonstrates Hyb&Count capture and detection of specific DNA labels.
[0159] [Figure 17B] FIG. 17B shows detection of targets in a 100plex capture panel.
[0160] [Figure 18] FIG. 18 shows the intensity distribution of the multicolor reporters.
[0161] [Figure 19] Figure 19 shows the error rates for the 14-class model (left) and the 10-class model (right).
[0162] [Figure 20] FIG. 20 shows a schematic of a two-color reporter probe.
[0163] [Figure 21] Figure 21 shows the probe hybridization workflow for targeted capture of nucleic acids.
[0164] [Figure 22] FIG. 22 shows targeted capture of nucleic acids for use in long-term phasing analysis of haplotypes.
[0165] [Figure 23] Figure 23 is a diagram illustrating a sequencing cycle using BC precomplexed with a cleavable RPTR, also known as a complementary nucleic acid molecule comprising a detectable label and a cleavable linker.
[0166] [Figure 24] FIG. 24 is a diagram illustrating a method for identifying each RPTR using RPTR cleavage and image subtraction.
[0167] [Diagram 25] FIG. 25 is a diagram of the generation of cleavable RPTR probes and shows examples of cleavable modifications.
[0168] [Figure 26] Figure 26 shows that the incubation time of hybridization was varied and the counts per field of view of the image display were used to determine the relative efficiency of the BC / RPTR complex compared to BC alone, followed by binding of RPTR in a second step. The BC and RPTR used are shown in Figure 27. Although the BC / RPTR complex shows slower binding kinetics than BC alone, similar binding efficiency can be achieved with longer incubation times.
[0169] [Figure 27] Figure 27 shows that image subtraction can be used to determine the identity of RPTR. BRAFex15-BC3 barcode was precomplexed with cleavable RPTR and processed for one full cycle. Four features are highlighted from a small portion of the image and the change in each fluorescence channel is shown in a bar graph. Cleavage was first performed on RPTR bound to spot 3 (sp3) using the USER enzyme mix (a mix of uracil DNA glycosylase (UDG) and DNA glycosylase-lyase-endonuclease VIII), followed by cleavage on spot 1 (sp1) using exposure to UV light. RPTR bound to spot 2 (sp2) was not cleavable.
[0170] [Figure 28] Figure 28 shows the detection and accurate identification of half-color GY RPTR upon cleavage. BC was complexed with one UV-cleavable RPTR and two non-cleavable PRTRs and hybridized to a DNA target immobilized on the surface of a flow cell. The fluorescence intensity of the RPTR was measured before and after UV exposure to cleave the single RPTR to determine the accuracy / range at which the half-color (i.e. GY instead of GG of the full-color RPTR) could be detected in the presence of another report.
[0171] [Figure 29]Figure 29 shows the detection and accurate identification of full-color GY RPTR upon cleavage for comparison with Figure 6. BC was complexed with one UV-cleavable RPTR and two non-cleavable PRTRs and hybridized to a DNA target immobilized on the surface of a flow cell. The fluorescence intensity of the RPTR was measured before and after UV exposure to cleave the single RPTR to determine the accuracy / range at which full-color (i.e. GG) could be detected in the presence of another report. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0172] The present invention provides probes, methods, kits and devices that provide accurate, rapid, sensitive, multiplexed detection, identification and quantification of target molecules in a sample. A probe for detecting one or more nucleic acids in a sample.
[0173] The present invention relates to a probe comprising a target binding domain and a barcode domain. The target binding domain and the barcode domain may be operably linked, for example covalently linked. The probe optionally comprises a spacer between said target binding domain and the barcode domain. The spacer can be any polymer having suitable mechanical properties, for example a single-stranded or double-stranded DNA spacer (of 1-100 nucleotides, for example 2-50 nucleotides). Non-limiting examples of double-stranded DNA spacers include sequences encompassed by SEQ ID NO:25 to SEQ ID NO:29. Additional exemplary sequences that can be included in the barcode domain are listed in SEQ ID NO:30 to SEQ ID NO:69.
[0174] Non-limiting examples of probes of the present invention are shown in Figures 1-5.
[0175] FIG. 1 is a diagram of a probe of the invention. This exemplary probe has a target binding domain of six nucleotides. The target binding domain of each probe has a known nucleotide sequence. The barcode domain contains one or more binding regions; in FIG. 1, there are six binding regions. A first binding region, a third binding region, and a fifth binding region are indicated. The fifth (fifth) position contains two binding regions. Each position on the barcode domain can have multiple binding regions. For example, a position may have 1-50 binding regions. Some positions in the barcode domain may have more binding regions than other positions (as shown at position 5 compared to positions 1-4 and 6). Alternatively, each position in the barcode domain has the same number of binding regions. Although not shown, each binding region contains at least one (i.e., 1-50, e.g., 10-30) copy of a nucleic acid sequence capable of reversibly binding to one complementary nucleic acid molecule (RNA or DNA). In FIG. 1, the binding regions are integral to the linear polynucleotide molecule that constitutes the barcode domain. The linear order of the binding positions and / or the sequence of positions identifies the particular region of the target nucleic acid to which the target binding domain binds.
[0176] FIG. 2 is a diagram of a probe of the invention. This exemplary probe has a target binding domain of 5 nucleotides. The target binding domain of each probe has a known nucleotide sequence. A first binding region is indicated; a first location on the barcode domain contains two first binding regions (non-essential) that are attached to the barcode domain. A fourth location on the barcode domain (containing a portion of the barcode domain and two fourth binding locations) is circled. Two sixth binding regions are indicated. Here, each location has two binding regions, but each location on the barcode domain may have one binding region or may have multiple binding regions, e.g., 2-50 binding regions. Although not shown, each binding region contains at least one (i.e., 1-50, e.g., 10-30) copy of a nucleic acid sequence that can reversibly bind to one complementary nucleic acid molecule (RNA or DNA). In FIG. 2, the barcode domain is a linear polynucleotide molecule to which the binding regions are linked / branched; said binding regions are non-essential to the polynucleotide molecule. The linear order of binding positions and / or the linear order of positions identifies the particular region of the target nucleic acid to which the target binding domain binds.
[0177] Figure 3 is another diagram of a probe of the invention. This exemplary probe has a target binding domain of 4 nucleotides. At each position, three binding regions are shown that are linked to and / or branched from that position.
[0178] FIG. 4 shows yet another diagram of a probe of the invention. This exemplary probe has a target binding domain of 10 nucleotides. However, only the first 6 nucleotides are specific for the target nucleic acid. Nucleotides 7-10 (denoted by "n1-n4") are added to increase the length of the target binding domain, thereby affecting the likelihood that the probe will hybridize and remain hybridized to the target nucleic acid. The "n" nucleotides have universal bases that can base pair with any of the four canonical bases (e.g., inosine, 2'-deoxyinosine (hypoxanthine deoxynucleotide) derivatives, nitroindoles, nitroazole analogs, and hydrophobic aromatic non-hydrogen bonding bases). In some embodiments, the "n" nucleotides can follow a specific nucleotide of the target binding domain. In FIG. 4, four "n" nucleotides are shown; however, the target binding domain may contain more or less than four "n" nucleotides. The target binding domain may lack "n" nucleotides. The second location includes six binding regions that are linked to and / or branch off from the second location of the barcode domain.
[0179] The target binding domain has at least 4 nucleotides, for example at least 4, 5, 6, 7, 8, 9, 10, 11, 12 or more nucleotides. The target binding domain may comprise 10-100, 20-160 or 35-50 nucleotides. The target binding domain is preferably a polynucleotide. The target binding domain is capable of binding a target nucleic acid.
[0180] The probe may comprise multiple copies of a target binding domain operably linked to a synthetic backbone.
[0181] Probes can be designed to adjust the likelihood of hybridization and / or dehybridization and the occurrence rate of them.In general, the lower the Tm of a probe, the more quickly and the more likely the probe will dehybridize from target nucleic acid.Therefore, using a probe with a low Tm will reduce the number of probes that bind to target nucleic acid.
[0182] The length of the target binding domain partially affects the likelihood of the probe to hybridize and remain hybridized to the target nucleic acid. In general, the longer the target binding domain (the more nucleotides), the lower the probability that a complementary sequence will exist in the target nucleic acid. Conversely, the shorter the target binding domain, the greater the probability that a complementary nucleic acid will exist in the target nucleic acid. For example, the probability that a 4-mer sequence will exist in the target nucleic acid is 1 / 256, whereas the probability that a 6-mer sequence will exist in the target nucleic acid is 1 / 4096. Thus, a set of shorter probes will be more likely to bind to more positions per given length of nucleic acid than a set of longer probes.
[0183] The term "target nucleic acid" refers to a nucleic acid molecule (DNA, RNA or PNA) whose presence in a sample is to be determined by the probes, methods and devices of the present invention. In general, "target nucleic acid", "nucleic acid molecule", "nucleic acid sequence", "nucleic acid", "nucleic acid fragment", "oligonucleotide" and "polynucleotide" are used interchangeably and include, but are not limited to, polymeric forms of either deoxynucleotides or ribonucleotides or analogs thereof that may be of various lengths. Non-limiting examples of nucleic acids include genes, gene fragments, exons, introns, intergenic DNA (including but not limited to heterochromatic DNA), messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, small interfering RNA (siRNA), non-coding RNA (ncRNA), cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of a defined sequence, isolated RNA of a defined sequence, nucleic acid probes, and primers.
[0184] In certain embodiments, the target molecule is not a chromosome. In other specific embodiments, the target molecule is 1,000 kb (1 mb) or less in size, 500 kb or less in size, 250 kb or less in size, 175 kb or less in size, 100 kb or less in size, 50 kb or less in size, 20 kb or less in size, or 10 kb or less in size. In yet other specific embodiments, the target molecule is isolated from its cellular environment.
[0185] The method identifies and quantifies nucleic acid molecules obtained from a sample, e.g., from a sample of an organism, preferably without a conversion (or amplification) step. As an example, in the case of an RNA identification method, the method can identify RNA without the need for prior conversion of the RNA molecule to a DNA molecule (i.e., without synthesis of cDNA). In most cases, since no amplification or conversion is required, the nucleic acid of the present invention will retain unique bases and / or epigenetic markers when the nucleic acid is present in the sample or when it is obtained from the sample. Such unique bases and / or epigenetic markers are lost in many methods known in the art.
[0186] The target nucleic acid can be obtained from any sample or source of nucleic acid, e.g., any cell, tissue or organism, in vitro, from a chemical synthesis device, etc. The target nucleic acid can be obtained by any method known in the art. In some embodiments, the nucleic acid can be obtained from a blood sample of a clinical subject. In some embodiments, the nucleic acid can be extracted, isolated, or purified from a source or sample using methods and kits known in the art.
[0187] As will be appreciated by those of skill in the art, a sample may be any number of entities, including, but not limited to: cells (including both primary cells and cultured cell lines), cell lysates or extracts (including, but not limited to, RNA extracts, purified mRNA), tissues and tissue extracts (including, but not limited to, RNA extracts, purified mRNA); bodily fluids (including, but not limited to, blood, urine, serum, lymph, bile, cerebrospinal fluid, interstitial fluid, aqueous humor or vitreous fluid, colostrum, sputum, amniotic fluid, saliva, vaginal and anal secretions, sweat and semen, exudates, transudates (e.g., from abscesses or other infections or Examples of samples that can be used include fluids obtained from sites of inflammation) or fluids obtained from joints (e.g. normal joints or joints affected by diseases such as rheumatoid arthritis, osteoarthritis, gout or septic arthritis), where mammalian samples are preferred, and human samples are particularly preferred; environmental samples (including but not limited to air, agricultural product, water and soil samples); biological (bacterial) weapon samples; research samples, such as extracellular fluids, extracellular supernatants from cell cultures, bacterial inclusion bodies, cellular compartments, periplasmic, mitochondrial compartments.
[0188] Biomolecular samples can be derived indirectly from biological specimens.For example, when the target molecule of interest is a cellular transcript, such as messenger RNA, the biomolecular sample of the present invention can be a sample containing cDNA produced by reverse transcription of messenger RNA.In another example, the biomolecular sample of the present invention is produced by subjecting biological specimens to fractionation, for example, size fractionation or membrane fractionation.
[0189] The biomolecular samples of the present invention may be either "native," i.e., unmanipulated or untreated, or "treated," which may involve any number of treatments, including exposure to candidate agents, including pharmaceuticals, genetic manipulation (e.g., adding or deleting genes).
[0190] Nucleic acid molecules, including target nucleic acids, can be fragmented by any means known in the art. Preferably, fragmentation is performed by enzymatic or mechanical means. Mechanical means can be sonication or physical shearing. Enzymatic means can be performed by digestion with a nuclease (e.g., deoxyribonuclease I (DNase I)) or one or more restriction endonucleases.
[0191] If the nucleic acid molecule which comprises the target nucleic acid is an intact chromosome, steps should be taken to avoid fragmenting the chromosome.
[0192] A target nucleic acid can contain naturally occurring nucleotides or non-naturally occurring nucleotides, including modified nucleotides, as is well known in the art.
[0193] The probe of the present invention may have a total length (target binding domain, barcode domain and any optional domains) of about 20 nanometers to about 50 nanometers. The backbone of the probe can be a polynucleotide molecule comprising about 120 nucleotides.
[0194] The barcode domain comprises a synthetic scaffold. The synthetic scaffold and the target binding domain are operably linked, for example, covalently linked or linked via a linker. The synthetic scaffold can be any material, for example, a polysaccharide, a polynucleotide, a polymer, a plastic, a fiber, a peptide, a peptide nucleic acid, or a polypeptide. Preferably, the synthetic scaffold is rigid. In one embodiment, the scaffold comprises a "DNA origami" of six DNA double helices (see, for example, Lin et al., Submicrometre geometrically encoded fluorescent barcodes self-assembled from DNA." Nature Chemistry, October 2012, 4(10): 832-9). The barcode can be made of DNA origami tiles (Jungmann et al., "Multiplexed 3D cellular super-resolution imaging with DNA-PAINT and Exchange-PAINT", Nature Methods, Vol. 11, No. 3, 2014).
[0195] The barcode domain comprises multiple positions, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more positions. The number of positions can be fewer, equal or more than the number of nucleotides in the target binding domain. In some embodiments, it is preferred that the target binding domain comprises additional nucleotides, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more additional nucleotides, than the number of positions in the scaffold domain. In some embodiments, the number of nucleotides in the target binding domain is at least twice the number of binding regions in the barcode domain. In additional embodiments, the number of nucleotides in the target binding domain is 8 and the number of binding regions in the barcode domain is 3. As stated above, the length of the barcode domain is not limited, as long as there is enough space for at least four positions.
[0196] Each position in the barcode domain comprises at least one binding region, e.g., 1-50 or more binding regions. One position in the barcode domain may have more binding regions than another position (e.g., a first position has three binding regions while a second position has two binding regions); alternatively, each position in the barcode domain has the same number of binding regions. Each binding region comprises at least one (i.e., 1-50, e.g., 10-30) copy number of a nucleic acid sequence that is reversibly bindable by a complementary nucleic acid molecule (e.g., DNA or RNA).
[0197] Each binding region can be linked to a modified monomer (e.g., a modified nucleotide) in the synthetic backbone such that the binding region branches off from the synthetic backbone. In some embodiments, the binding region is integral to the polynucleotide backbone; i.e., the backbone is a single polynucleotide and the binding region is part of the sequence of the single polynucleotide. In some embodiments, the terms "barcode domain" and "synthetic backbone" are synonymous.
[0198] For each probe, the nucleotide sequence of each binding region at one position is identical. Thus, in the probe, each first binding region at a first position has the same nucleotide sequence. Similarly, each ninth binding region at a ninth position has the same nucleotide sequence.
[0199] In the probe, each binding region or binding regions at one location will have a unique sequence. Also, the binding region at the first location will contain a different nucleic acid sequence than the binding region at the second location. Thus, no complementary nucleic acid molecule specific for the binding region at the second location will bind to the nucleic acid sequence in the binding region at the first location. Also, no complementary nucleic acid molecule specific for the binding region at the third location will bind to the binding region at the second location.
[0200] Each position on the barcode domain can contain one or more (up to 50, preferably 10-30) binding regions; thus, each binding region can bind one or more (up to 50, preferably 10-30) complementary nucleic acid molecules. In one embodiment, at least one position in the barcode domain contains multiple binding regions. In another embodiment, at least one position in the barcode domain contains more binding regions than another position. As an example, the probe in FIG. 1 has a fifth position that contains two binding regions, and the probe in FIG. 4 has a second position that has six binding regions. In one embodiment, the nucleotide sequences of the binding regions at one position are identical; thus, the complementary nucleic acid molecules that bind to those binding regions are identical.
[0201] In another embodiment, the nucleotide sequences of the binding regions at one position are not identical; thus, the complementary nucleic acid molecules that bind to those binding regions are not identical, e.g., each contains a different nucleic acid sequence and / or detectable label. Thus, in another embodiment, the combination of multiple non-identical nucleic acid molecules (e.g., their detectable labels) attached to the binding regions together provide a code for identifying a given nucleotide in the target nucleic acid.
[0202] Table 1 provides, for illustrative purposes only, exemplary sequences for a detectable label on the binding region and its binding complementary nucleic acid for a probe having six or fewer positions in the barcode domain.
[0203] [Table 1]
[0204] As shown in Table 1, the nucleic acid sequence of the first binding region can be one of SEQ ID NO:1 to SEQ ID NO:4; the nucleic acid sequence of the second binding region can be one of SEQ ID NO:5 to SEQ ID NO:8; and the nucleic acid sequence of the third binding region can be one of SEQ ID NO:9 to SEQ ID NO:12.
[0205] Table 1 shows that a given binding region can bind to one of four possible complementary nucleic acids containing detectable labels or reporter complexes containing detectable labels. Thus, if the binding region at the first location contains SEQ ID NO:1, the first location can be labeled with GFP; alternatively, if the binding region at the first location contains SEQ ID NO:2, the first location can be labeled with RFP. Detectable labels other than GFP, RFP, CFP and YFP may be used. Additionally, the nucleotide sequence of the binding region may differ from those listed in Table 1.
[0206] If the binding region at the first location comprises SEQ ID NO:1, the second binding region at the second location comprises SEQ ID NO:5, and the second binding region at the third location comprises SEQ ID NO:9, then the probe will have the first, second and third locations labeled with GFP. The GFP codes (i.e., the linear order of the detectable labels) of the three locations identify the target nucleic acid bound by the target binding site of the probe (e.g., GATA3).
[0207] However, for example, if the binding region at the first position comprises SEQ ID NO:1, the second binding region at the second position comprises SEQ ID NO:6, and the second binding region at the third position comprises SEQ ID NO:12, then the probe will have the first, second and third positions targeted with GFP, RFP and YFP, respectively. The GFP-RFP-YFP code (i.e., the linear order of the detectable labels) at the three positions identifies the target nucleic acid bound by the target binding site of the probe (e.g., MafB). Taken together, the selection of the binding region at each position defines a linear color code that the probe backbone can generate; this linear code is associated with a particular target nucleic acid that is complementary to the known nucleotide sequence of the target binding domain.
[0208] Similarly, for example, if the binding region at the first location comprises SEQ ID NO:1, the second binding region at the second location comprises SEQ ID NO:6, and the second binding region at the third location comprises SEQ ID NO:11, the probe will have first, second and third locations labeled with GFP, RFP and CFP, respectively. This three location GFP-RFP-CFP code (i.e., the linear order of the detectable labels) identifies the target nucleic acid bound by the target binding site of the probe (e.g., Fat3).
[0209] Taken together, three probes that bind to GATA3, MafB and Fat3, respectively, can be applied simultaneously to a sample and the presence and amount of each of GATA3, MafB and Fat3 can be detected by the differences in their linear order of detectable labels.
[0210] In one embodiment, a detectable label is attached to the complementary nucleic acid molecule, hi another embodiment, a reporter complex comprising a detectable label is attached to the complementary nucleic acid.
[0211] The nucleotide sequence of the complementary nucleic acid is not limited; preferably it lacks substantial homology (e.g., 50% to 99.9%) to known nucleotide sequences; this is useful to avoid undesired hybridization of the complementary nucleic acid with the target nucleic acid.
[0212] One example of a reporter complex useful in the present invention is shown in Figure 9B. In this example, a complementary nucleic acid is linked to (branched from) a first nucleic acid molecule which is then hybridized to a plurality of second nucleic acid molecules, each of which is then hybridized to a plurality of third nucleic acid molecules to which one or more detectable labels are attached.
[0213] In one embodiment, the first nucleic acid molecule can comprise about 90 nucleotides. The second nucleic acid molecule can comprise about 87 nucleotides. The third nucleic acid molecule can comprise about 15 nucleotides.
[0214] Figure 9C shows a typical population of reporter complexes. The top left panel of Figure 9C contains four complexes that hybridize to binding region 1 of the probe. For each possible nucleotide that can be present at nucleotide position 1 of the target binding domain of the probe, there is one type of reporter complex.
[0215] Reporter complexes can be of various designs. For example, a first nucleic acid molecule can hybridize to at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) second nucleic acid molecules. Each second nucleic acid molecule can hybridize to at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) third nucleic acid molecules. A typical reporter complex is shown in Figure 12A. In the figure, a "4x3" reporter complex has one first nucleic acid molecule (that is linked to / branched from complementary nucleic acid molecules) hybridized to four second nucleic acid molecules, each of which is hybridized to three third nucleic acid molecules (each containing a detectable label). In this figure, each complementary nucleic acid of the complex is 12 nucleotides in length ("12 bases"); however, the length of the complementary nucleic acid is non-limiting and can be less than or more than 12 nucleotides. The complex on the bottom right includes a spacer region between the complementary nucleic acid and the first nucleic acid molecule. The spacer is identified as being 20-40 nucleotides in length; however, the length of the spacer is not limiting and may be shorter than 20 nucleotides or longer than 40 nucleotides.
[0216] Figure 12B shows the fluctuating average (fluorescence) counts obtained from four exemplary reporter complexes shown in Figure 12A. In Figure 12B, 10 pM of biotinylated target template was bound onto a streptavidin-coated flow cell surface, and 10 nM of reporter complex was flowed over the flow cell. After 1 minute of incubation, the flow cell was washed, an image of the flow cell was taken, and the fluorescence features were counted.
[0217] In one embodiment, the reporter complexes are "pre-made", i.e., each polynucleotide in the complex is hybridized before the complex is contacted with the probe. A representative strategy for pre-making five exemplary reporter complexes is shown in Figure 12C.
[0218] FIG. 13A shows that the second nucleic acid molecule has an "extra handle" that is not hybridized to the third nucleic acid molecule and is distal to the first nucleic acid molecule. In this figure, each "extra handle" is 12 nucleotides in length ("12-mer"); however, their length is non-limiting and can be less than or more than 12 nucleotides. In one embodiment, each "extra handle" comprises the nucleotide sequence of a complementary nucleic acid; thus, when a reporter complex comprises an "extra handle", the reporter complex can hybridize to a probe via the reporter complex's complementary nucleic acid or via the "extra handle". Thus, the likelihood that the reporter complex will bind to the probe is increased. The "extra handle" design can also improve hybridization kinetics. Without being bound by theory, the "extra handle" essentially increases the effective concentration of the reporter complex's complementary nucleic acid.
[0219] FIG. 13B shows the fluctuating mean (fluorescence) counts obtained from five exemplary reporter complexes with "extra handles" using the procedure described in FIG. 12B.
[0220] Figures 14A and 14B show the hybridization kinetics and fluorescence intensity for two exemplary reporter complexes. By approximately 5 minutes, the total counts plateaued, indicating that most of the added reporter complexes had detected the available label.
[0221] The detectable moiety, label or reporter can be attached to the complementary nucleic acid or to a third nucleic acid molecule in various ways, for example, in the form of direct or indirect attachment of a detectable moiety, such as a fluorescent moiety, a colorimetric moiety, etc. The detectable label can include multiple detectable moieties, each having a distinct emission spectrum, which may be the same or different. For example, the detectable label can include multiple fluorophores, each having a distinct emission spectrum, which may be the same or different. The skilled artisan can consult references directed to labeling nucleic acids. Examples of fluorescent moieties include, but are not limited to, yellow fluorescent protein (YFP), green fluorescent protein (GFP), cyan fluorescent protein (CFP), red fluorescent protein (RFP), umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, cyanine, dansyl chloride, phycocyanin, phycoerythrin, etc. Fluorescent labels and their attachment to nucleotides and / or oligonucleotides are described in numerous reviews, such as Haugland, Handbook of Fluorescent Probes and Research Chemicals, 9th Edition (Molecular Probes, Inc., Eugene, 2002); Keller & Manak, DNA Probes, 2nd Edition (Stockton Press, New York, 1993); Eckstein, ed.; Oligonucleotides and Analogues: A Practical Approach (IRL Press, Oxford, 1991); and Wetmur, Critical Reviews in Biochemistry and Molecular Biology, 26: 227-259 (1991). Specific methodologies applicable to the present invention are disclosed, for example, in the following references: U.S. Patent Nos. 4,757,141, 5,151,507 and 5,091,519.In one aspect, one or more fluorescent dyes are utilized as labels for labeling target sequences, as disclosed, for example, by U.S. Pat. Nos. 5,188,934 (4,7-dichlorofluorescein dyes); 5,366,860 (spectrally resolvable rhodamine dyes); 5,847,162 (4,7-dichlororhodamine dyes); 4,318,846 (ether-substituted fluorescein dyes); 5,800,996 (energy transfer dyes); Lee et al., 5,066,580 (xanthine dyes); and 5,688,648 (energy transfer dyes). Targeting can be accomplished using quantum dots, as disclosed in the following patents and patent publications: U.S. Patents 6,322,901; 6,576,291; 6,423,551; 6,251,303; 6,319,426; 6,426,513; 6,444,143; 5,990,479; 6,207,392; 2002 / 0045045; and 2003 / 0017264. As used herein, the term "fluorescent label" includes signaling moieties that convey information through the fluorescent absorption and / or emission properties of one or more molecules. Such fluorescent properties include fluorescence intensity, fluorescence half-life, emission spectral properties, energy transfer, and the like. In a further non-limiting example, the fluorescent label can include any combination of the following fluorophores: Alexa Fluor® 350 (ALEXA FLUOR). TM 350), ALEXA FLUOR TM 405, ALEXA FLUOR TM 430, ALEXA FLUOR TM 532, ALEXA FLUOR TM 546, ALEXA FLUOR TM 568, ALEXA FLUOR TM 594 and ALEXA FLUOR TM 647.
[0222] Commercially available fluorescent nucleotide analogs that can be readily incorporated into nucleotide and / or oligonucleotide sequences include, but are not limited to, Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy5-dUTP (Amersham Biosciences, Piscataway, NJ), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red-5-dUTP (TEXAS RED TM -5-dUTP), Cascade Blue-7-dUTP(CASCADE BLUE TM -7-dUTP), Bodipy FL-14-dUTP (BODIPY TM FL-14-dUTP, BODIPY R-14-dUTP TM R-14-dUTP, TR-14-dUTP (BODIPY TM TR-14-dUTP), Rhodamine Green TM -5-dUTP (RHODAMINE GREEN TM 5-dUTP), Oregon Green R TM 488-5-dUTP, Texas Red-12-dUTP(TEXAS RED TM -12-dUTP), Bodipy 630 / 650-14-dUTP (BODIPY TM 630 / 650-14-dUTP, 650 / 665-14-dUTP (BODIPY) TM 650 / 665-14-dUTP), Alexa Fluor(TM) 488-5-dUTP(ALEXA FLUOR TM 488-5-dUTP), ALEXA FLUOR TM 532-5-dUTP, ALEXA FLUOR TM 568-5-dUTP, ALEXA FLUOR TM 594-5-dUTP, ALEXA FLUOR TM 546-14-dUTP, Fluorescein-12-UTP, Tetramethylrhodamine-6-UTP, Texas Red-5-UTP TM-5-UTP), mCherry, Cascade Blue-7-UTP(CASCADE BLUE TM -7-UTP), BODIPY TM FL-14-UTP, BODIPY TM R-14-UTP, BODIPY TM TR-14-UTP, Rhodamine Green-5-UTP(RHODAMINE GREEN TM -5-UTP), Alexa Fluor(TM) 488-5-UTP(ALEXA FLUOR(TM) TM 488-5-UTP), ALEXA FLUOR TM 546-14-UTP (Molecular Probes, Inc. Eugene, OR). Alternatively, the above fluorophores and those mentioned herein can be added during oligonucleotide synthesis, for example, using phosphoramidite or NHS chemistry. Routine synthesis protocols for nucleotides containing other fluorophores are known in the art (see Henegariu et al. (2000) Nature Biotechnol. 18:345). 2-Aminopurine is a fluorescent base that can be directly incorporated into the oligonucleotide sequence during its synthesis. Nucleic acids can also be pre-stained, for example, with intercalating dyes such as DAPI, YOYO-1, ethidium bromide, cyanine dyes (e.g., SYBR Green), and the like.
[0223] Additional fluorophores available for post-synthetic attachment include, but are not limited to, ALEXA FLUOR TM 350, ALEXA FLUOR TM 405, ALEXA FLUOR TM 430, ALEXA FLUOR TM 532, ALEXA FLUOR TM 546, ALEXA FLUOR TM 568, ALEXA FLUOR TM 594, ALEXA FLUOR TM647, BODIPY 493 / 503, BODIPY FL, BODIPY R6G, BODIPY 530 / 550, BODIPY TMR, BODIPY 558 / 568, BODIPY 558 / 568, BODIPY 564 / 570, BODIPY 576 / 589, BODIPY 581 / 591, BODIPY TR, BODIPY 630 / 650, BODIPY 650 / 665, Cascade Blue, Cascade Yellow, Dansyl, Lissamine Rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, Pacific Orange, Rhodamine 6G, Rhodamine Green, Rhodamine Red, Tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR), Examples include Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7 (available from Amersham Biosciences, Piscataway, NJ), etc. FRET tandem fluorophores can also be used, including, but not limited to, PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, APC-Cy7, PE-Alexa dyes (610, 647, 680), APC-Alexa dyes, etc.
[0224] Metallic silver or gold particles may be used to enhance the signal from fluorescently labeled nucleotide and / or oligonucleotide sequences (Lakowicz et al. (2003) BioTechniques 34:62).
[0225] Other suitable labels for oligonucleotide sequences include fluorescein (FAM, FITC), digoxigenin, dinitrophenol (DNP), dansyl, biotin, bromodeoxyuridine (BrdU), hexahistidine (6xHis), phosphorus-containing amino acids (e.g., P-tyr, P-ser, P-thr), etc. In one embodiment, the following hapten / antibody pairs are used for detection, where each antibody is derivatized with a detectable label: biotin / anti-biotin, digoxigenin / anti-digoxigenin, dinitrophenol (DNP) / anti-DNP, 5-carboxyfluorescein (FAM) / anti-FAM.
[0226] The detectable labels described herein are spectrally resolvable. "Spectrally resolvable" as used in reference to multiple fluorescent labels means that the fluorescent emission bands of the labels are sufficiently different, i.e., not overlapping, that the molecular tags to which each label is attached can be distinguished based on the fluorescent signal generated by each label using standard optical detection systems, such as those using bandpass filters and photomultiplier tube systems, as exemplified by the system described in Wheeless et al., Flow Cytometry: Instrumentation and Data Analysis (Academic Press, New York, 1985) pp. 21-76. In one embodiment, spectrally resolvable organic dyes, such as fluorescein, rhodamine, etc., mean that their emission maxima are at least 20 nm apart, and in another aspect, at least 40 nm apart. In another aspect, for chelated lanthanide compounds, quantum dots, etc., spectrally resolvable means that their emission maxima are at least 10 nm apart, and in another aspect, at least 15 nm apart. Nucleic Acid Detection Methods
[0227] The present invention relates to a method for detecting a nucleic acid using the probe of the present invention, an example of which is shown in Figures 6 to 11.
[0228] The method involves reversibly hybridizing at least one probe of the invention to a target nucleic acid that is immobilized on a substrate (eg, at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more positions).
[0229] The substrate can be any solid substrate known in the art on which a target nucleic acid can be immobilized, such as a coated slide or a microfluidic device. In some embodiments, the substrate is a surface, a membrane, a bead, a porous material, an electrode, or an array. The target nucleic acid can be immobilized on any substrate apparent to one of skill in the art.
[0230] In one embodiment, a target nucleic acid is bound by a capture probe that includes a domain that is complementary to a portion of the target nucleic acid, which can be a terminal or non-terminal portion of the target nucleic acid.
[0231] Exemplary useful substrates include those that contain a binding moiety selected from the group consisting of ligands, antigens, saccharides, nucleic acids, receptors, lectins, and antibodies. The capture probe contains a binding moiety that can bind to the binding moiety of the substrate. Such surfaces can be obtained from commercial sources or prepared according to standard techniques. Exemplary useful substrates that contain reactive moieties include, but are not limited to, epoxy, aldehyde, gold, hydrazide, sulfhydryl, NHS-ester, amine, thiol, carboxylate, maleimide, hydroxymethylphosphine, imidoester, isocyanate, hydroxyl, pentafluorophenyl ester, psoralen, pyridyl disulfide or vinyl sulfone, polyethylene glycol (PEG), hydrogel, or mixtures thereof. Exemplary useful substrates that contain reactive moieties include, but are not limited to, OptArray-DNA NHS group (Accler8), Nexterion Slide AL (Schott), and Nexterion Slide E (Schott).
[0232] In one embodiment, the binding moiety of the capture probe is biotin and the substrate comprises avidin (e.g., streptavidin). Useful substrates comprising avidin are commercially available, including, for example, TB0200 (Accelr8), SAD6, SAD20, SAD100, SAD500, SAD2000 (Xantec), SuperAvidin (Array-It), Streptavidin Slides (Cat. No. #MPC 000, Xenopore) and Streptavidin Slides (Cat. No. #439003, Greiner Bio-one).
[0233] In one embodiment, the binding moiety of the capture probe is avidin (e.g., streptavidin) and the substrate comprises biotin. Commercially available useful biotin-containing substrates include, but are not limited to, Optiarray-biotin (Accler8), BD6, BD20, BD100, BD500 and BD2000 (Xantec).
[0234] In some embodiments, the binding moiety of the capture probe can comprise a reactive moiety that can be bound to the substrate by photoactivation.The substrate may comprise a photoreactive moiety, or the first part of the nanoreporter may comprise a photoreactive moiety.Some examples of photoreactive moieties include aryl azides, such as N((2-pyridyldithio)ethyl)-4-azidosalicylamide; fluorinated aryl azides, such as 4-azido-2,3,5,6-tetrafluorobenzoic acid; benzophenone-type reagents, such as the succinimidyl ester of 4-benzoylbenzoic acid; and 5-bromodeoxyuridine.
[0235] In some embodiments, the binding moiety of the capture probe can be immobilized to the substrate via another binding partner that will be apparent to one of skill in the art.
[0236] Once attached to the substrate, the target nucleic acid can be elongated by applying a force sufficient to stretch the target nucleic acid (e.g., gravity, hydrodynamic force, electromagnetic force, "electrostretching", flow stretching, receding meniscus techniques and combinations thereof).
[0237] The target nucleic acid can be bound by a second capture probe that includes a domain that is complementary to a second portion of the target nucleic acid. The portion can be at or off the end of the target nucleic acid. The binding of the second capture probe can occur after or during the extension of the target nucleic acid, or it can occur to the unextended target nucleic acid. The second capture probe can have a binding as described above.
[0238] The capture probe may contain or be associated with a detectable label, ie, associated with a reference spot.
[0239] A capture probe can isolate a target nucleic acid from a sample. In this case, the capture probe is added to a sample containing a target nucleic acid. The capture probe binds to a region of the target nucleic acid through a region of the capture probe that is complementary to a region of the target nucleic acid. When the target nucleic acid is contacted with a substrate that contains a moiety that binds to the binding moiety of the capture probe, the nucleic acid becomes immobilized to the substrate.
[0240] To ensure that the user can "capture" as many target nucleic acid molecules as possible from a highly fragmented sample, it is useful to include multiple capture probes, each complementary to a different region of the target nucleic acid. For example, there may be three pools of capture probes, a first pool that is complementary to a region of the target nucleic acid, a second pool that is complementary to a region in the middle of the target nucleic acid, and a third pool that is a region near its 3' end. This can be generalized as "n-regions-of-interest" for each target nucleic acid. In this example, each separate pool of fragmented target nucleic acid contains or is bound to one biotin label. 1 / nth n of input samples (where n = number of distinct regions in the target nucleic acid) are isolated for each pool chamber. The capture probe binds the target nucleic acid of interest. The target nucleic acid is then immobilized to an avidin molecule attached to the substrate via the biotin on the capture probe. Optionally, the target nucleic acid is stretched, for example by hydrodynamic or electrostatic forces. All n pools can be stretched and bound simultaneously, or to maximize the number of fully stretched molecules, pool 1 (capturing most of the 5′ region) can be stretched and bound first; then pool 2 (capturing the middle of the target region) can be stretched and bound; and finally pool 3 can be stretched and bound.
[0241] The number of different capture probes required is inversely proportional to the size of the target nucleic acid fragment. In other words, a larger number of capture probes will be required for highly fragmented target nucleic acids. For sample types with highly fragmented and degraded target nucleic acids (e.g., formalin-fixed paraffin foam tissue), it is useful to include multiple pools of capture probes. On the other hand, for samples with long target nucleic acid fragments, such as isolated nucleic acids obtained in vitro, a single capture probe at the 5' end is sufficient.
[0242] The probe or capture probe of the present invention may each contain one or more affinity reagents selected from the group consisting of antigens, carbohydrates, nucleic acids, receptors, lectins, haptens and antibodies. The affinity reagents allow purification of the complex formed by the probe or capture probe and the target nucleic acid. Such purification increases the concentration of the target nucleic acid to be detected.
[0243] In one embodiment, the affinity reagent is biotin and the purification means (eg, bound to a solid substrate) comprises avidin (eg, streptavidin).
[0244] In one embodiment, the affinity reagent is avidin (eg, streptavidin) and the purification means (eg, bound to a solid substrate) comprises biotin.
[0245] In one embodiment, the affinity reagent comprises a nucleic acid having a known sequence. Thus, a probe or capture probe comprising the affinity reagent can be purified from a sample using a purification probe comprising a nucleic acid complementary to the affinity reagent. Similarly, a complex comprising a probe or capture probe comprising the affinity reagent can be purified from a sample using a purification probe comprising a nucleic acid complementary to the affinity reagent. The affinity components of a probe or capture probe directed to the same target nucleic acid can have different nucleic acid sequences. Alternatively, the affinity reagent of a probe and the affinity reagent of a capture probe directed to the same target nucleic acid can have the same nucleic acid sequence. The affinity reagent of each probe in a population of probes can have the same nucleic acid sequence. The affinity reagent of each probe in a population of capture probes can have the same nucleic acid sequence. The affinity reagent of each probe in a population of probes can have a different nucleic acid sequence. The affinity reagent of each probe in a population of probes can have a different nucleic acid sequence.
[0246] In one embodiment, the affinity reagent is a hapten and the purification means (eg, bound to a solid substrate) comprises a protein binding domain (eg, an antibody).
[0247] FIG. 5A is an illustration of a probe bound to a target nucleic acid. Here, the target nucleic acid comprises a sequence of TCAGTG. The barcode domain of the probe was designed to have a binding region that specifically identifies the bound TCAGTG by a particular linear color code or "linear order of detectable labels". A first pool of complementary nucleic acids or reporter complexes comprising detectable labels is shown at the top of the figure, with each member of the pool having a different nucleotide sequence and an associated detectable label (e.g., a green color label and a cyan color label). As an example, the nucleic acids of the first pool have sequences complementary to SEQ ID NOs: 1-4 of Table 1. In FIG. 5A, the first binding region of the probe comprises one or more nucleotide sequences that specify that the first position is to be labeled with a cyan color label (e.g., the binding region comprises SEQ ID NO: 3 of Table 1). Thus, only complementary nucleic acids that are specific for the first binding position and that carry a cyan label can bind to the first position of the barcode domain of the depicted probe. The cyan label is the first (first) color in the linear color code that identifies the bound target nucleic acid.
[0248] The color associated with the first location is image analyzed and recorded in the system of the present invention.
[0249] The number of pools of complementary nucleic acids or reporter complexes is the same as the number of positions in the barcode domain, so for a barcode domain with 6 positions, 6 pools will be cycled across the probe.
[0250] When a capture probe is added to a sample containing a target nucleic acid, the probe may be presented to the target nucleic acid first (see Figure 6). Such probes may be presented at different concentrations, different buffer conditions, e.g., salt, and different temperatures to increase sensitivity and specificity for the target nucleic acid.
[0251] Capture probes and probes can possess affinity reagents for multi-step purification (see Figure 7 and Figures 8A-8E). Such purification can be used alone or can be purified from both ends. Purification will increase the specificity and purity of target capture.
[0252] A probe can be first provided and bound to a target nucleic acid that is completely devoid of a detectable label or a complementary nucleic acid comprising a reporter complex that includes a detectable label. Such a probe will be smaller in size than a probe that includes a detectable complementary nucleic acid. Such a probe can be provided in higher concentrations than a probe that includes a detectable label. Such a small probe will bind to the target nucleic acid more quickly and efficiently, thus providing data in fewer time fractions than using a probe that includes a detectable label.
[0253] Alternatively, the probe can be hybridized to a complementary nucleic acid that includes a detectable label or reporter complex at its first location prior to contacting the target nucleic acid with the probe, and since the probe can emit a detectable signal from its first location when contacted with its target nucleic acid, it is not necessary to provide a first pool of complementary nucleic acids or reporter complexes that are directed to its first location on the barcode domain.
[0254] Figure 5B is a continuation of the method shown in Figure 5A, where the first complementary nucleic acid (or reporter complex) bound to the binding region of the first position of the barcode domain is replaced with a first hybridizing nucleic acid that does not have a detectable label. The first hybridizing nucleic acid that does not have a detectable label replaces the already bound complementary nucleic acid or already bound reporter complex that contains a detectable label. As a result, the first position of the barcode domain no longer emits a detectable signal.
[0255] The hybridizing nucleic acid without a detectable label can comprise a sequence identical to the previously bound complementary nucleic acid or previously bound reporter complex that comprises a detectable label (SEQ ID NO: 1 to SEQ ID NO: 24). Preferably, the hybridizing nucleic acid without a detectable label will be longer than the previously bound complementary nucleic acid or previously bound reporter complex that comprises a detectable label. Thus, the hybridizing nucleic acid further comprises a sequence that is complementary to a single-stranded polynucleotide or polynucleotide analog adjacent to the binding region. Without being bound by theory, a hybridizing nucleic acid that is longer than the associated complementary nucleic acid that comprises a detectable label will have a greater affinity for the barcode domain and will more easily displace the complementary nucleic acid that comprises a detectable label. Such hybridizing nucleic acids that are longer than the associated complementary nucleic acid are shown in Figures 10 and 11.
[0256] In some embodiments, the complementary nucleic acid containing a detectable label or reporter complex can be released from the binding region but cannot be replaced by a hybridizing nucleic acid that does not have a detectable label. This can be done, for example, by adding a chaotropic agent, increasing the temperature, changing the salt concentration, adjusting the pH, and / or applying a hydrodynamic force. In these embodiments, fewer reagents (i.e., hybridizing nucleic acids that do not have a detectable label) are required.
[0257] 5C is a continuation of the method of the invention. A second pool of complementary nucleic acids or reporter complexes is shown at the top (having sequences complementary to SEQ ID NO:5-8 in Table 1), with each member of the pool having a different detectable label and a different nucleotide sequence. Furthermore, the nucleotide sequences of the complementary nucleic acids of the first pool or the reporter complexes are different from those of the second pool. Here, only complementary nucleic acids from the second pool that contain a yellow detectable label bind to the second position of the barcode domain (e.g., the complementary nucleic acid has a sequence complementary to SEQ ID NO:8 in Table 1).
[0258] The color associated with the second location is imaged and recorded in the system of the present invention.
[0259] In one embodiment, the steps shown in Figure 5C are followed by the steps shown in Figure 5B, where the first pool of complementary nucleic acids or reporter complexes (in Figure 5A) is replaced with a first hybridizing nucleic acid without a detectable label (Figure 5B), and then a second pool of complementary nucleic acids or reporter complexes is provided (as shown in Figure 5C). Alternatively, the steps shown in Figure 5C are performed simultaneously with the steps shown in Figure 5B, where the first hybridizing nucleic acid without a detectable label (Figure 5B) is provided simultaneously with the second pool of complementary nucleic acids or reporter complexes (as shown in Figure 5C).
[0260] Figure 5D is a continuation of the method shown in Figure 5C, where the first through fifth positions on the barcode domain are bound by complementary nucleic acids that contain a detectable label or reporter complex, the colors associated with those positions are imaged and recorded, and the complementary nucleic acids are replaced with hybridizing nucleic acids that do not have a detectable label. The sixth position of the barcode domain is now bound by a complementary nucleic acid that contains a detectable label or reporter complex, which identifies the sixth position in the target binding domain as being bound to a guanine (G).
[0261] The color associated with the sixth location is imaged and recorded in the system of the present invention.
[0262] At this point, the entire linear color code (i.e., the linear sequence of the detectable labels) of the probe backbone is detected; this linear code is then associated with a specific target nucleic acid that is complementary to the known nucleotide sequence of the target binding domain. As an example, a probe that can emit a linear color code of green, cyan, red, yellow, yellow, red can bind to Fat2. Thus, if the system of the present invention records a linear color code of green, cyan, red, yellow, yellow, red, the user will know that Fat2 was present in the sample.
[0263] Because each color associated with a probe backbone domain is detected sequentially, it may be unnecessary to extend the probe backbone to identify and separate each color label, which is an advantage over previous generations of nucleic acid detection probes.
[0264] As noted above, complementary nucleic acid containing a detectable label or reporter complex can be released from the binding region, but cannot be replaced by a hybridizing nucleic acid that does not have a detectable label.
[0265] If necessary, the rate of displacement of the detectable label can be enhanced by incorporating a small single-stranded oligonucleotide that enhances the rate of displacement of the detectable label (e.g., a "Toe-Hold" probe; see, e.g., Seeling et al., "Catalyzed Relaxation of a Metastable DNA Fuel", J. Am. Chem. Soc. 2006, 128(37), 12211-12220).
[0266] Similar to Figures 5A-5D, Figures 9A and 9D-9F show steps of the method of the invention; however, Figures 9A and 9D-9F clearly show that a reporter complex (containing a detectable label) is bound to the binding region of the probe. Figures 9D and 9E show that a fluorescent signal is continuously emitted from the probe hybridized to the reporter complex.
[0267] FIG. 10 summarizes the steps shown in FIGS. 9D and 9E. At the top of the figure, the nucleotide sequence of a typical probe is shown and the important domains of the probe are identified. The probe contains an optional double-stranded DNA spacer between its target binding domain and the barcode domain. The barcode domain contains, in order, a "Flank 1" portion, an "AR-1" portion, an "AR-1 / Flank 2" portion, an "AR-2" portion, and an "AR-2 / Flank 3" portion. In Step 1, "AR-1 Detect" hybridizes to the "AR-1" and "AR-1 / Flank 2" portions of the probe. "AR-1 Detect" corresponds to a reporter complex or complementary nucleic acid that includes a detectable label that codes for a thymidine at the first position. Thus, Step 1 corresponds to FIG. 9D. In Step 2, "Lack 1" hybridizes to the "Flank 1" and "AR-1" portions of the probe. "Lack 1" corresponds to a hybridizing nucleic acid that does not have a detectable label specific to the first binding region of the probe (shown as a black bar covering the first binding region in FIG. 9E). By hybridizing to the "Flank 1" portion 5' of the reporter complex or complementary nucleic acid, the hybridizing nucleic acid effectively displaces the reporter complex / complementary nucleic acid from the probe. The "Flank" portion is also known as "Toe-Hold". In Step 3, "AR-2 Detect" hybridizes to the "AR-2" portion and the "AR-2 / Flank 3" portion of the probe. "AR-2 Detect" corresponds to a reporter complex or complementary nucleic acid that includes a detectable label that encodes a guanine at the second position. Thus, Step 3 corresponds to FIG. 9E. In this embodiment, a hybridizing nucleic acid without a detectable label and a complementary nucleic acid that includes a detectable label / reporter complex are provided consecutively.
[0268] Alternatively, a hybridizing nucleic acid without a detectable label and a complementary nucleic acid containing a detectable label / reporter complex are provided simultaneously. This alternative embodiment is shown in Figure 11. In Step 2, "Lack 1" (a hybridizing nucleic acid without a detectable label) is provided together with "AR-2 Detect" (a reporter complex encoding "guanine" at the second position). This alternative embodiment may be more time-efficient than the embodiment summarized in Figure 10 because it merges two steps into one.
[0269] The detectable label of the present disclosure can be detected by any means known in the art.For example, the detectable label can be detected by a system that includes one or more of a microscope, a camera, a microprocessor, and / or a computer system.In one aspect, the camera is a CCD camera.In one aspect, the microscope, the camera, and the computer system can include a complementary metal oxide semiconductor (CMOS chip). Multiplex detection of multiple nucleic acids
[0270] In some embodiments, multiple nucleic acids are detected simultaneously, i.e., multiplexed. For this purpose, a set or group of different probes are provided to a sample of immobilized nucleic acid targets. The set or group of probes preferably includes at least two, e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more types of probes.
[0271] A set of probes can be predefined based on the cell type or tissue type that is targeted.For example, if the tissue is breast cancer, the probe set will include probes directed to nucleic acids that are expressed in association with breast cancer cells (e.g., Her2, EGFR and PR) and / or probes directed to nucleic acids that are expressed in normal breast tissue.In addition, the set of probes can be predefined based on the developmental state of the cell or tissue that is targeted.
[0272] NanoString Technologies' nCounter® system and methods enable the simultaneous multiplexed identification of a large number (over 800) of different target proteins and / or target nucleic acids. Definition:
[0273] In one exemplary embodiment, the terms "annealing" and "hybridization" are used interchangeably herein to refer to the formation of a stable duplex. In one aspect, a stable duplex is one that is not disrupted by stringent washing under conditions such as a temperature that is either about 5°C below or about 5°C above the Tm of the duplex and a low monovalent salt concentration, such as 0.2M below or 0.1M below salt concentrations known to those of skill in the art. The term "perfectly matched" as used in reference to a duplex means that the polypeptide and / or oligonucleotide strands that make up the duplex form a duplex structure with each other such that all nucleotides of each strand are Watson-Crick base paired with the nucleotides of the other strand. The term "duplex" includes, but is not limited to, pairing of nucleoside analogs, such as deoxyinosine, nucleosides with 2-aminopurine bases, PNAs, etc., that may be used. A "mismatch" in a duplex between two oligonucleotides means that a pair of nucleotides in that duplex cannot make Watson-Crick bonds.
[0274] As used herein, the term "hybridization conditions" will typically include salt concentrations less than about 1M, more usually less than about 500 mM, and even more usually less than about 200 mM. Hybridization temperatures can be as low as 5°C, but are typically higher than 22°C, more typically higher than about 30°C, and often greater than about 37°C. Hybridization is generally performed under stringent conditions, e.g., conditions under which the probe specifically hybridizes to its target subsequence. Stringent conditions are sequence-dependent and vary for different environments. Longer fragments may require higher hybridization temperatures for specific hybridization. Other factors, including base composition and length of complementary sequences, the presence of organic solvents, and the degree of base mismatch pairing, can also affect the stringency of hybridization, so the combination of parameters is more important than the absolute measurement of any one alone.
[0275] In general, stringent conditions are selected to be about 5°C lower than the Tm value of a specific sequence at a defined ionic strength and pH. Exemplary stringent conditions include a salt concentration of at least 0.01 M to 1 M Na ion (or other salt) at pH 7.0-8.3 and a temperature of at least 25°C. For example, conditions of 5xSSPE (750 mM NaCl, 50 mM Na phosphate, 5 mM EDTA, pH 7.4) and a temperature of 25-30°C are suitable for allele-specific probe hybridization. For stringent conditions, see, for example, Sambrook, Fritsche & Maniatis, "Molecular Cloning A Laboratory Manual, 2nd Edition", Cold Spring Harbor Press (1989) and Anderson Nucleic Acid Hybridization, 1st Edition, BIOS Scientific Publishers Limited (1999). As used herein, the term "specifically hybridizes to" or "specifically hybridizes to" or similar terms refers to a molecule that substantially binds, duplexes, or hybridizes to one or more specific nucleotide sequences under stringent conditions.
[0276] A detectable label associated with a particular position on a probe can be "read" (e.g., its fluorescence is detected) one or more times; here "read" can be synonymous with "basecall." Multiple reads improve accuracy.
[0277] As used herein, "Hybe & seq cycle" refers to all the steps required to detect each binding region on a particular probe or group of probes.For example, in the case of a probe that can detect six positions on a target nucleic acid, one "hybe & seq cycle" will include at least hybridizing the probe to the target nucleic acid; hybridizing complementary nucleic acid / reporter complexes to the binding region at each of the six positions on the barcode domain of the probe; and detecting the detectable label associated with each of the six positions.
[0278] The term "k-mer probe" is synonymous with the probe of the present invention.
[0279] The methods described herein can be implemented and / or recorded using any device capable of implementing the methods and / or recording the results. Examples of devices that can be used include, but are not limited to, electronic computing devices, including all types of computers. When the methods described herein are implemented and / or recorded in a computer, the computer program used to configure a computer to perform the steps of the method can be contained in any computer readable medium capable of containing the computer program. Examples of computer readable media that can be used include, but are not limited to, diskettes, CD-ROMs, DVDs, ROMs, RAMs, non-removable readable media, and other memory and computer storage devices. The computer program that can be used to configure a computer to perform the steps of the method, identify the bound labeled nucleic acid, and / or record the results can also be provided via an electronic network, such as the Internet, an intranet, or other networks.
[0280] The "Consumable Card" can be incorporated into fluorescence imaging devices known in the state of the art. Any fluorescence microscope with a wide variety of features can perform this readout. For example: wide-field lamps, lasers, multiphoton, confocal or total internal reflection illumination can be used for excitation and / or detection. Cameras (monocular or multi-lens cameras) and / or photomultipliers with either filters or grating spectral resolution (one or more spectrally resolved emission wavelengths) can be placed on the emission detection channel of the fluorescence microscope. A standard computer can control both the consumable card (through which the reagents flow) and the detection by the fluorescence microscope.
[0281] The probes can be detected and quantified using commercially available cartridges, software and systems, for example the nCounter® system using the nCounter® cartridge.
[0282] Additional teachings related to the present invention may be found in one or more of the following publications: US 8,148,512, US 7,473,767, US 7,919,237, US 7,941,279, US 8,415,102, US 8,492,094, US 8,519,115, US 2009 / 0220978, US 2009 / 0299640, US 2010 / 0015607, US 2010 / 0261026, US 2011 / 0086774, US 2011 / 0145176, US 2011 / 0201515, US 2011 / 0229888, US 2013 / 0004482, US No. 2013 / 0017971, US 2013 / 0178372, US 2013 / 0230851, US 2013 / 0337444, US 2013 / 0345161, US 2014 / 0005067, US 2014 / 0017688, US 2014 / 0037620, US 2014 / 0087959, US 2014 / 0154681, US 2014 / 0162251 and US 14 / 946,386, the entire contents of each of which are incorporated herein by reference.
[0283] Any of the above aspects and embodiments may be combined with any other aspect or embodiment as disclosed in the "Summary and / or Specific Description" section of this specification. EXAMPLES
[0284] Example 1: The present invention provides rapid and efficient detection of target nucleic acids.
[0285] In Figure 15A, the "mini-barcode" probe contained a barcode sequence and a target detection sequence within the 30-50 mer range. "Probe B" had a specific sequence (30-50 mer) and a universal tag containing biotin for attachment to surfaces.
[0286] High concentrations of probes can be provided and applied to samples containing target nucleic acids. The probes of the present invention can be provided at concentrations 10 to 1000 times higher than probes containing detectable labels. Such high probe concentrations are, in part, responsible for providing rapid detection of target nucleic acids.
[0287] In FIG. 15B, the probe was provided at 250 picomolar (pM) and in FIG. 15C, it was provided at 2.5 nanomolar (nM). In another experiment using the standard nCounter workflow, the probe containing the detectable label was provided at 25 pM. In FIG. 15A, the capture probe was provided at 100 pM and in FIG. 15B, the capture probe was provided at 2.5 nM. In another experiment using the standard nCounter workflow, the capture probe containing the detectable label was provided at 100 pM. FIGS. 15A and 15B show that the target nucleic acid can be detected after 10 minutes. Significant target detection in those experiments could be achieved in about 2 hours with the low concentration probe and within about 30 minutes with the high concentration probe (FIG. 16A). In another experiment using the standard nCounter workflow, the probe containing the detectable label required about 17.5 hours to detect the target nucleic acid.
[0288] Figure 16A shows the average counts when four target nucleic acids were detected simultaneously using the probes and methods of the invention. Here, the four target nucleic acids were Myc (green), Oazl (blue), RPL13A (orange) and TubB (red). Probes and capture probes were provided at 2.5 nM and the target nucleic acids were 100 ng of human reference RNA. Figure 16B shows that the method of the invention is about 9 times more efficient than the method in which the probes are provided with detectable labels (labeled "Sprint" in the figure). These results demonstrate a significant increase in efficiency in a significantly shorter time compared to the standard nCounter workflow. Example 2: Sample preparation for processing FFPE tissues used in Hyb & Count
[0289] First, nucleic acids to be sequenced were extracted from formalin-fixed paraffin-embedded (FFPE) tissues in a one-step process. One or more 10 μm thick FFPE curls were heated in an aqueous nucleic acid extraction buffer, simultaneously melting the paraffin wax, degrading the tissue, and releasing the nucleic acids from the cells. Suitable extraction buffers are known in the art and typically contain proteinase, detergent such as Triton®-100, chelating agents such as EDTA, and ammonium ions. The FFPE curls and extraction buffer were incubated at 56° C. for 30 minutes to separate the paraffin from the tissue, and the tissue structures were digested with proteinase K, and the embedded cells were exposed to detergent for cell lysis. The solution was inverted three times at 8-minute intervals to facilitate mixing of reagents during the tissue deparaffinization and digestion steps. After this step, the solution was heated to 98° C. to facilitate reversal of formaldehyde crosslinks, thereby further facilitating extraction of nucleic acids.
[0290] Once the nucleic acids were extracted from the FFPE tissues, the solution was filtered using glass fiber filters (Whatman) with 2.7 μm pore size to remove tissue debris and solidified paraffin. The resulting solution was a homogenous translucent solution containing nucleic acids that were highly fragmented due to the formalin fixation and storage conditions. If further fragmentation was required, they could be mechanically sheared using a Covaris focused ultrasonicator. Due to the buffer conditions, extended sonication was necessary to shear the nucleic acids. The greatest increase in captured targets was achieved using sonication for 600 seconds using standard settings of 50 watts (W) maximum incident power, 20% duty factor, and 200 cycles / burst (as shown). To obtain shorter fragment lengths, the emulsified paraffin can be precipitated from the filtered solution by centrifugation at 21,000 × g and 4 °C for 15 minutes. This treatment allows DNA to be sheared down to approximately 225 bp.
[0291] Target capture was then performed by binding the capture probe pair to the target in a rapid hybridization step. The 5' capture probe contains a 3' biotin moiety that binds the target to a streptavidin-coated flow cell surface in a target attachment step. The 3' capture probe contains a 5' tag sequence (G sequence) that can be bound to beads during the purification step. The reaction rate is dictated by the capture probe concentration, and capture probes are added in the low nanomolar range to maximize the reaction rate. The capture probe hybridizes to the target in such a way that it flanks the region of interest to create a window. For each DNA target, the capture probe further contains an oligo that hybridizes to the antisense strand of the target and consists of the same sequence as the window to prevent reannealing. The solution containing the capture probe was heated to 98°C for 3 minutes to denature the genomic DNA, and then incubated at 65°C for 15 minutes. NaCl concentrations ranging from 400 mM to 600 mM were used for this hybridization reaction. The panel of over 100 experimentally validated targets is listed in Table 2, which provides gene and exon details of the targeted DNA regions. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4]
[0292] After the target DNA regions were bound to the capture probes, they were purified from the remainder of the genomic DNA to obtain a concentrated solution of the targets. Beads coated with antisense oligos (anti-G sequences) against the binding sequence of the 3' capture probe were incubated with the capture reaction mixture for 15 minutes at room temperature. After the binding step, the beads were washed three times with 0.1x SSPE to remove non-target DNA and the biotin-containing 5' capture probe. After washing, the beads were resuspended in 14 μL of 0.1x SSPE and then heated at 45°C for 10 minutes to elute the purified DNA targets from the beads. After elution, 1 μL of 5M NaCl was added to ensure that the capture probes remained bound to the DNA targets.
[0293] The final step in the sample preparation process is the attachment of DNA targets onto the flow cell surface, where they can be analyzed using the probes of the present invention as disclosed herein. A syringe pump was used to control the rate at which targets were loaded into the flow cell fluidic channel, so that all targets had time to diffuse over the channel height and bind to the streptavidin surface. This loading method creates a density gradient of targets, where the maximum number of molecules per unit area is greatest at the inlet of the fluidic channel and decreases along the channel length in the direction of fluid flow toward the outlet. For a 1.6 mm wide and 40 μM high channel, a flow rate of 0.35 μL / sec achieves quantitative capture within a channel length of approximately 10 mm. Once targets were bound to the surface by the biotinylated 5′ capture probe, a solution of biotinylated oligo (G-hook), which is the inverse complement of the binding sequence of the 3′ capture probe, was injected to locate the free ends of the targets and create a bridge structure. In this case, the central ssDNA region is the window of interest. A solution of G-sequence oligos was then added to hybridize to the excess G-hooks, reducing the amount of ssDNA on the surface.
[0294] To identify enriched targets, 15-mer probes were designed that could specifically bind to a single target in the panel. The probes were synthesized with an adapter sequence on the 3′ end that could attach them to a unique barcode oligo. Each barcode oligo contained three reporter binding domains that could bind to a reporter probe for target identification, allowing a 64-plex readout using four-color reporter chemistry. The identification probes were injected into the fluidic channel, incubated for 1 min, and allowed to hybridize to the targets. Unbound and non-specifically bound oligos were then removed using a stringent wash of 0.1×SSPE. Three rounds of reporter probe hybridization were used to identify targets based on their unique barcodes. The use of target-specific identification probes in combination with a dual capture probe system to capture specific regions of the genome provides a highly specific system for target enrichment and detection. Figure 17A depicts a specificity analysis in which a panel of 40 targets was captured and enumerated from 3 μg of purified sheared gDNA. Lane 1 represents the total target detection counts when all capture probes are used together compared to lane 2 where no gDNA is present. The specificity of the system was confirmed by including in the system only capture probes that enrich for targets detected by the blue and yellow (B&Y) reporter in lane 3 or the green and red (G&R) reporter in lane 4.
[0295] This DNA extraction, capture and detection workflow was applied to three FFPE tissue types: tendon, lung and melanoma. For all tissue types, capture and detection of a 100-plex cancer target panel resulted in >95% of labels identified within 1-log homogeneity. Counts of those labels across the three tissue types are displayed in Figure 17B. Example 3: Multicolor reporter imaging for Hyb & Seq
[0296] The image processing pipeline includes the following steps: background subtraction, registration, feature detection and classification. In background subtraction, the average background of a given channel is a function of shot noise and exposure. In our system, the blue channel has the highest background level coupled with a larger variance. A simple tophat filter with a circular structuring element of radius 7 pixels was applied to perform local background subtraction.
[0297] Registration is essential so that features of interest are perfectly aligned for multi-color and multi-circulation feature analysis. The system requires two forms of registration. In the first form, a local affine (pseudo) transformation is applied to all image channels in a single acquisition stack. This transformation is a function of the optics and is therefore consistent (common) for a given instrument. This function is pre-computed for each run and applied to all acquired images. In the second form, a global transformation in the form of a fixed shift is computed using normalized cross-correlation analysis that accounts for drift of the mechanical gantry between runs.
[0298] The next step is feature detection. Once all images are registered, features are detected using a matched filter with a LoG (Laplace of Gaussian) filter. The matched filter with a fixed kernel size (matched to the diffraction limit of the feature) and variation standard deviation (matched to the wavelength of the corresponding channel) was applied to enhance the spot response. Local maxima were used to identify potential reporter locations. The intensity values associated with each identified feature were retrieved and retrieved for classification.
[0299] The final step is classification. Multicolor reporter intensities were classified using a Gaussian naive Bayesian estimation model. This model assumes that reporter intensities follow independent normal distributions. The model then uses the following MAP (maximum a posteriori) law:
number
number
[0300] The intensity distribution of the reported dual color code is shown in Figure 18. This figure summarizes the decoding method using the two dyes blue and red. Six classes (including background) are possible in the two-color decoding scenario. In the implemented system, the choice of four colors resulted in 14 potential classes. It should be noted that there is some overlap between the single half-dye versus full-dye distributions. As a result, classification between those classes gave high error rates as shown in Figure 19, with the maximum misclassification rate between "xG" and "GG" being 11.8%. The misclassification rate in the 10-class model was less than 0.2%. Since each reporter requires a maximum of eight classes, it is straightforward to select the one with the smallest classification error.
[0301] Example 4: Function, design, preparation, and testing of two-color reporter probes
[0302] The two-color reporter probe binds sequentially to three regions (R1, R2, R3) in the barcode domain of the probe. Each region codes for eight "colors" defined by two-color fluorescent combinations such as "blue-blue" or "green-yellow". Three consecutive "colors" are reported for each probe, which then correspond to the reading of the three dinucleotides that make up the hexamer. The two-color reporter probe is designed as follows: a 37 DNA oligomer branched structure designed to carry 15 fluorescent dyes for each color, with a total of 30 dyes per reporter probe. The 37 oligomers were classified into three sizes: (1) one 96 nt MainBranch (main strand) consisting of a 12-mer single-stranded DNA sequence that was later used to report the hexamer and two parts, six 14-mers hybridized to six SubBranches (minor strands); (2) six 89 nt SubBranches (minor strands) each consisting of one 14-mer hybridized to the MainBranch and five 15-mer repeat sequences hybridized to five Dye oligos; (3) five 15 nt Dye oligos each having one fluorescent dye modification at the 5' end of the oligo.
[0303] One of the critical design features of the two-color reporter probe is to have different SubBranch and Dye oligo sequences among the four different fluorochromes. This prevents possible "color-swapping" or cross-hybridization between the different fluorochromes. For example, each 15-mer Dye oligo for the Alexa 488 fluorophore (blue) corresponds to a sequence that is complementary only to the blue SubBranch. The blue SubBranch further has a separate 14-mer sequence that is complementary only to the blue 14-mer sequence on the MainBranch and not to the yellow, red, or green sequences. Thus, a particular MainBranch will have a specific two-color sequence that dictates which of the 15 plus 15 dye combinations it will carry.
[0304] Another important design characteristic of the two-color reporter probe is the 12-mer sequence on the MainBranch, which must satisfy the following: (1) different 12-mer sequences among R1, R2 and R3; (2) encoding eight different colors per region with high specificity; (3) high binding efficiency and uniformity among the eight different colors; and (4) efficient removal of all 12-mer sequences from competing toehold sequences.
[0305] Two-color reporter probes were prepared as follows: four fluorescent dyes (B=blue, G=green, Y=yellow, R=red) make ten possible two-color combinations (BB, BG, BR, BY, GG, GR, GY, RR, YR, YY). Only eight of the ten two-color combinations were used in each of the three barcode domains of the probe, generating 24 different reporter probes (8+8+8=24).
[0306] The preparation of the two-color reporter probes was performed in two sequential hybridization steps: (1) hybridization of Dye oligo to SubBranch; then (2) hybridization of Dye+SubBranch to MainBranch. Four separate Dye-to-SubBranch reactions were prepared by mixing 100 μM SubBranch and 600 μM Dye oligo in 4.2×SSPE buffer at room temperature for 30 min. Twenty-four reporter probes were then prepared using 2 μM MainBranch, 7.2 μM SubBranch+Dye 1, and 7.2 μM SubBranch+Dye 2 in 4.8×SSPE separately. The reactions were kept at 45°C for 5 min and then cooled to room temperature for 30 min. The 24 Dye+SubBranch-to-MainBranch reactions were pooled into three different pools (i.e., R1, R2, R3) corresponding to the barcode domains. For example, eight different two-color reporter probes (2 μM each) that bind to the R1 barcode domain were pooled together and diluted 10-fold to a final working concentration of 200 nM of each reporter probe.
[0307] Standard tests for quality assurance are performed after reporter probe preparation. Each of the three pools of reporter probes was tested for binding to its corresponding barcode region (i.e., R1, R2, R3) in three separate flow cells. Testing was performed on modified probe constructs in which only the barcode domain was present and immobilized on the flow cell. All eight 12-mers displaying each color were multiplexed, and it is expected that all eight two-color reporter probes would be identified with high color counts.
[0308] A schematic of the two-color reporter probes is shown in Figure 20. The probes are used in a simple probe hybridization workflow for targeted capture of nucleic acids (depicted in Figure 21). Figure 22 shows the additional capabilities of these probes in relation to their use in identifying haplotypes of interest.
[0309] Example 5: Three two-color reporter probes and image removal
[0310] This example illustrates the pre-hybridization of three reporter complexes to a sequencing probe in solution prior to binding to a surface-immobilized target. Solution hybridization has been shown to be much more efficient than surface hybridization and can be advantageously performed in sequencing experiments, greatly reducing total sample-to-answer run times. The identity of the three reporters was determined by sequentially cleaving the reporters off the sequencing probe (by chemical or optical methods) and measuring the decrease in fluorescence intensity.
[0311] The present disclosure requires hybridization of one of a set of 4096 barcode molecules (BC), each of which is a possible hexamer sequence, to a target molecule immobilized on the surface of a flow cell, where a region of the barcode domain is described herein as a probe that may be bound by a complementary nucleic acid molecule containing a detectable label or a complementary nucleic acid molecule of a reporter complex containing a detectable label. The identity of the barcode, the associated hexamer sequence in the target, requires the binding and readout of three two-color fluorescent reporter probes (RPTR), also described herein as a complementary nucleic acid molecule containing a detectable label or a complementary nucleic acid molecule of a reporter complex containing a detectable label. The RPTRs are flowed through the flow cell, hybridized to the BCs, imaged, and removed by toe-holding in a sequential manner, requiring three RPTR flows for each BC readout.
[0312] Figure 23 shows the hybridization of all three RPTR probes to the BC before flowing through the flow cell. The BC / RPTR complex can be purified before use to ensure that nearly 100% of the BC / RPTR complexes are correctly formed. The BC / RPTR complexes were hybridized to the target on the surface and an image was acquired containing the fluorescent signals from all six colors (three two-color RPTRs). One of the reporters was then cleaved, releasing the fluorescent dye from the complex. The cleavage mechanism is discussed in more detail herein. A second image was then acquired containing the fluorescent signals from only four colors (two two-color RPTRs).
[0313] As shown in Figure 24, the identity of the lost RPTR can be obtained by comparing the six-color image with the four-color image. Then, a different cleavage mechanism is used to remove the second RPTR, and a third image containing fluorescent signals from two colors (one two-color RPTR) is obtained. Similarly, the identity of the cleaved RPTR is determined by comparing the two-color image with the four-color image. The residual fluorescent signal indicates that the third RPTR uniquely identifies the BC, and thus the hexamer sequence is present in the target.
[0314] As shown in FIG. 25, the cleavable RPTRs used in the first two reads of the sequencing cycle are constructed similarly to the non-cleavable version, consisting of 30 Dyed oligos hybridized to six "Sub-Branch" oligos (also described herein as the third nucleic acid molecule), which are finally hybridized to a "Main-Branch" oligo (also described herein as the second nucleic acid molecule). These RPTRs are made cleavable by synthesizing a "Main Branch" oligo in which several cleavable modifications, such as one or more of photocleavable, chemically cleavable, and enzymatically cleavable modifications, are placed between the portion of the "Main Branch" that binds the BC and the portion that binds the "Sub-Branch" and the dye. An example of a chemically cleavable modification is a disulfide moiety. An example of an enzymatically cleavable modification is a deoxyuracil (dU)-containing moiety (which can be cleaved using the "USER" enzyme from New England Biolabs). The cleavable modifications used in the two RPTRs within one sequencing cycle must be different to allow sequential cleavage.
[0315] The key properties and advantages of this method are: (1) BC / RPTR complexes can be prepared prior to a sequencing run allowing for greater control during hybridization; (2) this method has the potential to greatly increase the number of BCs uniquely identified because (a) the BC / RPTR complexes can be HPLC purified to ensure that each BC has all three RPTRs, and (b) the cleavage efficiency is significantly higher than that of RPTR hybridization and toeholding; (3) this method is much faster in terms of sequencing run time because (a) no hybridization time is required for each RPTR to bind to a BC, (b) the cleavage kinetics to release the RPTR signal are significantly faster than toeholding (based on hybridization), and (c) it requires many fewer reagent flow steps (8 steps versus 14 for the current method, and only 6 flow steps even when using a UV-cleavable linker). The present method requires the acquisition of fewer images (4 versus 7 for the current method, and 3 versus 6 even if the final water wash dark image is omitted).
[0316] A proof of principle experiment was performed using a single BC, a UV-cleavable RPTR, a deoxyuracil (dU)-containing RPTR (cleavable using the "USER" enzyme mix from New England Biolabs) and a standard RPTR. The components were hybridized into a BC / RPTR complex and hybridized to a 50-mer synthetic BRAF exon 15 target sequence immobilized on a flow cell. The identity of the spots was determined by first acquiring a first image of the complete BC / RPTR complex, then treating with USER enzyme to remove the dU-containing RPTR, and acquiring a second image again. The photocleavable RPTR was then cleaved by exposure to UV light and a third image was acquired, as shown in FIG. 27. The four clustered features in the images were processed, their fluorescence intensities were measured, and a simple subtraction was performed to accurately identify the identity of the three RPTRs.
[0317] The main potential risk of this approach was the size of the BC / RPTR complex and the slowing of hybridization kinetics to the surface-immobilized target. The increased size of the BC / RPTR complex compared to BC alone does indeed slow down the binding kinetics; however, this can be overcome by using longer incubation times as shown in Figure 26. The loss in hybridization time here can be offset by efficiency and speed reductions in other steps (i.e., removal of the RPTR hyb, reductions (simplifications) in image processing steps, reductions in flow steps).
[0318] We also tested whether half-pigment-RPTRs could be detected using this image subtraction method. Since their pigments have similar signals, they may be much more difficult to identify reliably. To test this, we prepared a set of barcodes with multiple similarly colored RPTRs (mostly green and yellow), with only the spot 1 RPTR being cleavable, as shown in Figures 28 and 29. Images were acquired before and after UV exposure to cleave the spot 1 RPTR. Both PPC-GY and PC-GG were detectable, producing intensity changes similar to those predicted by the number of pigments lost (e.g., GYYYGY RPTR cleaved to _YYGY lost 50% of its green (G) and 25% of its yellow (Y)). The set of pigment colors, classes, and associated sequences are shown in the table below. [Table 3]
Claims
[Claim 1] 1. A probe comprising a target binding domain and a barcode domain: the target binding domain comprises at least four nucleotides and is capable of recognizing and binding to a specific region of a target nucleic acid; the target binding domain comprises a known nucleotide sequence; at least one of the nucleotides in the target binding domain is a locked nucleic acid (LNA); the barcode domain comprises a first binding region comprising a nucleic acid sequence that is bound by a first complementary nucleic acid molecule or a first hybridizing nucleic acid molecule, and at least a second binding region comprising a nucleic acid sequence that is bound by at least a second complementary nucleic acid molecule or at least a second hybridizing nucleic acid molecule; the first complementary nucleic acid molecule or the first hybridizing nucleic acid molecule comprises a first detectable label, such that the first detectable label binds to the first binding region; the at least a second complementary nucleic acid molecule or the at least a second hybridizing nucleic acid molecule comprises a second detectable label, whereby the second detectable label binds to the at least a second binding region; and the sequence of the first binding region is different from the sequence of the at least second binding region; probe.
Citation Information
Patent Citations
Chase ligation sequencing method
JP2010539982A
Allele-specific mutation detection assay
US20060088872A1
Methods for sequencing of a necleic acid
US7745129B1
Sequencing by structure assembly
WO2013055995A2
Diagnostic assay combining cellular and cell free nucleic acid
WO2014182598A1
